



PWYLLGOR ADNODDAU CYNALIADWY SUSTAINABLE RESOURCES COMMITTEE

DYDDIAD Y CYFARFOD: DATE OF MEETING:	28 February 2023
TEITL YR ADRODDIAD: TITLE OF REPORT:	Finance Report and Forecast Month 10 2022/23
CYFARWYDDWR ARWEINIOL: LEAD DIRECTOR:	Huw Thomas, Director of Finance
SWYDDOG ADRODD: REPORTING OFFICER:	Rebecca Hayes, Senior Finance Business Partner

Pwrpas yr Adroddiad (dewiswch fel yn addas)

Purpose of the Report (select as appropriate)

Ar Gyfer Trafodaeth/For Discussion

ADRODDIAD SCAA SBAR REPORT

Sefyllfa / Situation

The purpose of the report, attached at Appendix 1, is to outline Hywel Dda University Health Board's (HDdUHB) financial position to the end of the financial year 2022/23 against the Annual Plan.

The Committee is asked to note the detail included within Appendices 1a and 2, which provides the full commentary and tables submitted to Welsh Government (WG) as part of the Health Board's reporting requirements. The monthly reporting is in line with the written report provided to the Sustainable Resources Committee and Board.

Cefndir / Background

The Health Board's revised draft Financial Plan is to deliver a deficit of £62.0m, after savings of £13.9m; this recognises the inadequate level of assurance around the identification of a further £15.5m of savings schemes deliverable within the current financial year against our initial £25.0m deficit Plan, combined with an operational variation due to system pressures and continuation of COVID-19 activities within our core services.

The forecast deficit is £59.0m, after recognising a further £5.0m of operational variation offset by £8.0m Accountancy Gains.

Month 10 position:

- The Month 10 Health Board financial position is an overspend of £6.2m, which is made up of £4.1m operational variance and an original deficit plan of £2.1m; this is after recognising £0.3m of WG transitional funding for COVID-19. £1.4m of savings schemes were delivered in line with identified plans.
- Of the £4.1m overspend in-month, £1.1m relates to undelivered savings plans against the original target and £3.0m relates to operational pressures. These pressures are mainly being experienced within our Unscheduled Care teams, but also within Medicines Management in relation to Primary Care Prescribing and in Oncology due to increased activity.

- The Health Board has received confirmation of WG funding to match the costs of the COVID-19 programmes (Tracing, Testing, Mass Vaccinations and Personal Protective Equipment (PPE), and also to match the costs of the COVID-19 Transitional Responses and Exceptional Energy up to a maximum of the Month 8 and 6 forecast respectively. WG funding has been received in respect of the Health and Social Care Levy, Exceptional Real Living Wage commissioned costs and the Pay Award.

End of Year Forecast

- Since our initial plan submission, each Executive Director and their respective leadership teams have been reviewing their operational plans to deliver a step change through targeted programmes of work. Trajectories are being developed, but as yet limited assurance can be taken for in-year financial benefit realisation. This represents a significant concern with regards to the underlying deficit into the new financial year.
- Of the identified operational savings schemes of £13.9m, only a small number are currently assessed as recurrent, with a full year effect of £2.0m. This is contributing to the deterioration in the underlying deficit to £80.0m from the brought forward 2021/22 position of £68.9m, which presents a challenge to be addressed as part of our targeted programmes of work. In addition to the operational schemes, a non-recurrent Accountancy Gain of £8.0m has been identified in relation to the part release of an Annual Leave carryover provision following Workforce Policy confirmation.

Asesiad / Assessment

The Health Board's key targets are as follows:

- Revenue: to contain the overspend within the Health Board's planned deficit
- Savings: to deliver savings plans to enable the revenue budget to be achieved
- Capital: to contain expenditure within the agreed limit
- PSPP: to pay 95% of Non-NHS invoices within 30 days of receipt of a valid invoice
- Cash: While there is no prescribed limit for cash held at the end of the month, WG encourages this to be minimised and a rule of thumb of 5% of monthly expenditure is used. For the Health Board, this is broadly £4.0m.

Key target		Annual limit	YTD limit	Actual delivery	Forecast Risk
Revenue	£'m	59.0	46.2	46.4	Medium*
Savings	£'m	21.9	19.7	19.7	Low**
Capital	£'m	33.2	18.6	18.6	Low
Non-NHS PSPP	%	95.0	95.0	95.0	Low***
Period end cash	£'m	4.0	4.0	2.4	Low****

* The Health Board is forecasting a financial outturn position of £59.0m, which is an improvement against the re-submitted draft annual plan of £62.0m, which is £34.0m higher than the previous planned deficit of £25.0m. Whilst the delivery risk to the revised forecast deficit of £59.0m is considered to be Low, this is an unacceptable level of deficit and urgent management actions are required to address the underlying position; given the expected worsening of the underlying position due to pressures, particularly in Unscheduled Care, Primary Care Prescribing and drugs, the risk has been escalated to Medium given the trajectory.

** Of the identified operational savings schemes of £13.9m, only a small number are currently assessed as recurrent, with a full year effect of £2.0m. This is contributing to the deterioration in the underlying deficit to £80.0m from the brought forward 2021/22 position of £68.9m, which presents a challenge to be addressed as part of our 2023/24 planning cycle. In addition to the

operational schemes, a non-recurrent Accountancy Gain of £8.0m has been identified in relation to the part release of an Annual Leave carryover provision.

***The Health Board has now achieved its PSPP target of paying 95% of its non-NHS invoices within 30 days in Quarter 3, and the cumulative position at Month 10 is 95.2%. There remains a Low risk, given the failure in Quarter 2 (93.6%) caused by delays in authorising invoices by the service and the remaining concern due to staff shortages within specific areas. Work continues to support process improvements to further improve the cumulative position.

**** WG have confirmed that Strategic Cash funding will be made available in line with the Health Board's request to fund the cash consequences of the revenue deficit.

Cash

As the Committee will be aware, earlier in the year a Cash Strategy paper was presented outlining a cashflow prediction up to the end of 2022/23. The paper also included various scenarios as to how we would manage our cash position through the potential non-payment of various categories (1 to 5) of expenditure.

Our cash run rate is currently at a higher level than originally forecast, which may result in a requirement to initiate a review of our payment policy in respect of categories 5, 4 and 3.

Inefficiency activity drivers

As the outcome of work surrounding the allocation of resources, based on our population health needs compared to national benchmarks, inefficiency activity drivers are articulated with financial quantification.

The strategic activity drivers that are having an adverse impact on our financial deficit are split into the three macro elements; Demand, Supply and Configuration, and Efficiency. The organisation has work programmes, led by Executive Directors, to implement improvement activities for each specific micro driver articulated.

Unscheduled Care Configuration broadly relates to the number of hospital sites and front doors the Health Board currently manages, which is linked to our long-term strategy, so will not have a financial improvement in the short-term.

Directorate		Demand	Supply			Configuration & Efficiency				Totals
		Ready to leave patients	Agency premium: Medical	Agency premium: Nursing	CHC (s117)	Medically fit patients	Multiple site (A&E & Inpatient)	Multiple site (OP)	Multiple site (Planned Care)	
Unscheduled Care Configuration							16.6	0.8		17.4
Carmarthenshire County		4.0		0.1						4.1
Ceredigion County		2.9								2.9
Pembrokeshire County		3.7		0.2						3.9
Unscheduled Care Bronglais			0.5	0.2		1.8				2.4
Unscheduled Care Glangwili			0.3	2.1		4.3				6.7
Unscheduled Care Prince Philip			0.3	1.2		3.9				5.4
Unscheduled Care Withybush			0.4	1.9		5.6				7.9
Women & Children			0.5	0.2						0.8
Planned Care			1.2	0.8				0.7	1.1	3.7
Mental Health & Learning Disabilities	Carms Pembs Cered		0.3	0.9						1.2
					4.9					4.9
					2.2					2.2
					2.9					2.9
Diagnostics									2.0	2.0
		10.6	3.4	7.5	10.0	15.5	16.6	1.5	3.1	
		10.6			21.0				36.7	68.3

Argymhelliad / Recommendation

The Sustainable Resources Committee is asked to note and discuss the financial position as at Month 10 alongside the implications for the Health Board of the challenging outlook.

Amcanion: (rhaid cwblhau)

Objectives: (must be completed)

Committee ToR Reference: Cyfeirnod Cylch Gorchwyl y Pwyllgor:	4.5 Provide assurance on financial performance and delivery against Health Board financial plans and objectives and, on financial control, giving early warning on potential performance issues and making recommendations for action to continuously improve the financial position of the organisation, focusing in detail on specific issues where financial performance is showing deterioration or there are areas of concern.
Cyfeirnod Cofrestr Risg Datix a Sgôr Cyfredol: Datix Risk Register Reference and Score:	1199 (score 25) Achieving financial sustainability.

Safon(au) Gofal ac Iechyd: Health and Care Standard(s):	5. Timely Care 7. Staff and Resources
Amcanion Strategol y BIP: UHB Strategic Objectives:	All Strategic Objectives are applicable
Amcanion Cynllunio Planning Objectives	All Planning Objectives Apply
Amcanion Llesiant BIP: UHB Well-being Objectives: Hyperlink to HDdUHB Well-being Objectives Annual Report 2018-2019	9. All HDdUHB Well-being Objectives apply

Gwybodaeth Ychwanegol: Further Information:	
Ar sail tystiolaeth: Evidence Base:	Monitoring returns to Welsh Government based on HDdUHB's financial reporting system.
Rhestr Termau: Glossary of Terms:	Contained within the report
Partïon / Pwyllgorau â ymgynhorwyd ymlaen llaw y Pwyllgor Adnoddau Cynaliadwy: Parties / Committees consulted prior to Sustainable Resources Committee:	Finance Team Management Team Executive Team

Effaith: (rhaid cwblhau) Impact: (must be completed)	
Ariannol / Gwerth am Arian: Financial / Service:	Financial implications are inherent within the report.
Ansawdd / Gofal Claf: Quality / Patient Care:	The impact on patient care is assessed within the savings schemes.
Gweithlu: Workforce:	The report considers the financial implications of our workforce.
Risg: Risk:	Financial risks are detailed in the report.
Cyfreithiol: Legal:	HDdUHB has a legal duty to deliver a breakeven financial position over a rolling three-year basis and an administrative requirement to operate within its budget within any given financial year.

Enw Da: Reputational:	Adverse variance against HDdUHB's financial plan will affect its reputation with Welsh Government, Audit Wales, and with external stakeholders.
Gyfrinachedd: Privacy:	Not applicable.
Cydraddoldeb: Equality:	Not applicable.

Hywel Dda UHB

Month 10 YTD Financial Performance and EoY Forecast

Sustainable Resources Committee

28th February 2023


Month 10 Executive Summary

Health Board's revised draft Financial Plan is to deliver a deficit of £62.0m, after savings of £13.9m; this recognises the inadequate level of assurance around the identification of a further £15.5m of savings schemes deliverable within the current financial year against our initial £25.0m deficit Plan, combined with an operational variation due to system pressures and continuation of COVID-19 activities within our core services. The forecast deficit is £59.0m, after recognising a further £5.0m of operational variation offset by £8.0m Accountancy Gains.

Financial position	Month 9 £'m	Month 10 £'m	YTD £'m	EOY £'m
Original Planned deficit	2.1	2.1	20.9	25.0
Undelivered Savings plans	1.5	1.1	12.8	15.5
Operational variance (including transfers from COVID-19)	1.1	3.0	18.5	26.5
COVID-19 expenditure	1.9	1.1	19.7	22.3
Accountancy gain	0.0	0.0	(8.0)	(8.0)
Operational variance before WG COVID-19 funding	6.6	7.3	63.9	81.3
WG COVID-19 funding: 'Programme' costs	(0.8)	(0.6)	(11.1)	(12.5)
WG COVID-19 funding: 'Other' costs	(0.8)	(0.2)	(2.7)	(2.9)
WG COVID-19 funding: 'Transitional' costs	(0.3)	(0.3)	(5.9)	(6.9)
Reported financial position	4.7	6.2	44.2	59.0

- Financial pressures continue across the Health Board where a combination of high activity, vacancies and sickness are driving significant variable pay expenditure particularly within acute sites and Radiology. In Medicines Management, a combination of prescription growth and the price of standard items, Category M and NCSO drugs are adversely affecting run rates.
- The Health Board is working through the Targeted Intervention Framework under the four key themes of: 1) Analysis of the drivers from a £25.0m deficit to a £67.0m deficit; 2) Continuous development and implementation of the Opportunities framework; 3) Organisation's Delivery framework; 4) Review of financial management arrangements.
- As a result of the analysis of the deficit drivers, it is expected that the assessment of the underlying deficit will show a deterioration from £80.0m to a worst case scenario of £94.7m; this is being taken through the Board governance process before formalising.
- Further development of Improving Together framework, Integrated finance and performance Directorate management meetings.

Month 10 In-Month 2022/23: Key drivers (£'m)



The value of £0.3m is the Transitional funding allocation to match non-programme transitional COVID-19 costs incurred. £0.6m of funding has been assumed to match Exceptional Energy costs. Both funding streams are capped at a maximum of the Month 10 EoY forecast which presents a risk to the EoY position.

Programme funding relates to the following in response to COVID-19 match-funded by WG:

- TTP
- COVID-19 mass vaccination programme
- PPE

£0.6m was released to match costs in Month 10.

Operational variance excluding unidentified savings is £5.2m; underspends in non-USC not materialising to offset £2.1m of non-COVID-19 overspend.

Month 10 In-Month 2022/23: Key drivers (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
Undelivered Savings	1.1	0.0	1.1	Non COVID-19: In month undelivered savings against plan.
Medicines Management	0.9	0.0	0.9	Non COVID-19: The financial overspend is driven by items growth of 1.27% and a significant increase in cost per item of £7.93 seen in October data (+£0.66 Oct 21) included within these figures is the significant increase in the number of drugs listed on the NCSO concession list YTD.
USC GGH	0.8	0.0	0.8	Non COVID-19: With continued front door pressures ,with site on Black for 1 day,Red for 19 days with Surge beds on average 38 with highest at 44 beds. Pay £563k - Nursing £380k, Substantive vacancies remain high which has resulted in 91.56 wte of agency shifts booked in month. Medical Staff £116k over due to Locum & Medacs usage in Gen Med & A&E covering vacancies and pilot scheme to improve discharges. Non Pay £208k overspent- Mainly drugs £129k over & unfunded SLA's £20k & unfound historical savings target.
Oncology	0.6	0.0	0.6	Non COVID-19: Drugs £610k overspend - SACT activity increased 30% (includes 9% in year) since 19/20, far in excess of previously funded growth. This therefore brings a prior year drugs growth cost pressure of 15% plus a further 18% pressure in year due to the activity growth, along with transition of Enzalutamide patients to homecare (previously WP10s). Pay vacancies improve position but offset by increased consumable spend, drug transport and Chemocare maintenance costs.

Month 10 In-Month 2022/23: Key drivers (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
USC WGH	0.5	0.1	0.6	<p>Non COVID-19: Site pressures continue with 30 patients on discharge pathways, an average of 40 surge beds (35 in m9) with a peak of 47 (41 in m8) and an average of 24 patients in A&E needing a bed. As at 1st February we have 77 medically optimised patients against a bed base of 199. As a result, medical staffing is £213k overspent and nursing £191k overspend. Additionally, we have a £60k non pay overspend driven by drugs, particularly on high cost gastro drugs, again as a direct result of site pressures.</p> <p>COVID-19: Driven by continued staffing of Puffin Ward through a mix of substantive and agency/bank staff.</p>
USC BGH	0.4	0.0	0.4	<p>Non COVID-19: Continued pressure in January with 18 red days. Presence of covid remains the same as December. Average 11 unplaced in ED and average of 29 medically optimised patients with 4 ready to leave. Continued sickness in nursing and increased sickness in medical plus agency to fill vacancy gaps resulting in increased variable pay costs incurred in month. Clinical supplies & drugs cost pressure reflecting continued surge activity.</p>
USC PPH	0.4	0.0	0.4	<p>Non COVID-19: With site on 17 Red Days with surge beds particularly high for the first half of the month & medically fit, ready to leave remaining at high levels. Pay increased to £225k over - Nursing & HCSW £120k overspent, with increased agency costs due to continued vacancies and sickness rates as previous months. Medical Staff £67k over due to continued locum usage in Gen Med & historical unfunded Consultant post. Non Pay £214k overspent - insulin pumps & consumables reduced to £76k over due to block purchases in December & drugs increased to £124k.</p>
Mental Health & LD	(0.4)	0.0	(0.4)	<p>Non COVID-19: Income (2.6K) Re-charges in respect of CAMHS Mental Health Advisors. Pay (425K) High levels of vacancies Substantive (£624K) offset by £249K variable pay. (Bank £164K and Agency £40K and £41K locum costs). Main vacancies Nursing (£306k) off set £32k agency and £59K bank to cover sick + vac, Medical (£45k) offset by £42k locum costs. Non Pay = 28.3K Drugs 54K Higher volumes M10 comparison to Previous M9 delayed expenditure..(20K) Supplies + Services drop off old accrual Powys Invoice CAMHS Forensic Services.</p>

Month 10 In-Month 2022/23: Deviation from prior forecast (£'m)



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Hywel Dda
University Health Board



Note: Within the £0.9m reported as other directorate movements, £1.1m relates to the in month movement in risk mitigation.

Month 10 In-Month 2022/23: Deviation from prior forecast (£'m)



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Hywel Dda
University Health Board

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
USC WGH	0.5	0.1	0.6	Non COVID-19: Site pressures continue with 30 patients on discharge pathways, an average of 40 surge beds (35 in m9) with a peak of 47 (41 in m8) and an average of 24 patients in A&E needing a bed. As at 1st February we have 77 medically optimised patients against a bed base of 199. As a result, medical staffing is £213k overspent and nursing £191k overspend. Additionally, we have a £60k non pay overspend driven by drugs, particularly on high cost gastro drugs, again as a direct result of site pressures. COVID-19: Driven by continued staffing of Puffin Ward through a mix of substantive and agency/bank staff.
USC BGH	0.4	0.0	0.4	Non COVID-19: Continued pressure in January with 18 red days. Presence of covid remains the same as December. Average 11 unplaced in ED and average of 29 medically optimised patients with 4 ready to leave. Continued sickness in nursing and increased sickness in medical plus agency to fill vacancy gaps resulting in increased variable pay costs incurred in month. Clinical supplies & drugs cost pressure reflecting continued surge activity.
USC PPH	0.4	0.0	0.4	Non COVID-19: With site on 17 Red Days with surge beds particularly high for the first half of the month & medically fit, ready to leave remaining at high levels. Pay increased to £225k over - Nursing & HCSW £120k overspent, with increased agency costs due to continued vacancies and sickness rates as previous months. Medical Staff £67k over due to continued locum usage in Gen Med & historical unfunded Consultant post. Non Pay £214k overspent - insulin pumps & consumables reduced to £76k over due to block purchases in December & drugs increased to £124k.
Mental Health & LD	(0.4)	0.0	(0.4)	Non COVID-19: Income (2.6K) Re-charges in respect of CAMHS Mental Health Advisors. Pay (425K) High levels of vacancies Substantive (£624K) offset by £249K variable pay. (Bank £164K and Agency £40K and £41K locum costs). Main vacancies Nursing (£306k) off set £32k agency and £59K bank to cover sick + vac, Medical (£45k) offset by £42k locum costs. Non Pay = 28.3K Drugs 54K Higher volumes M10 comparison to Previous M9 delayed expenditure..(20K) Supplies + Services drop off old accrual Powys Invoice CAMHS Forensic Services.

Month 10 In-Month 2022/23: Deviation from prior forecast (£'m)



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Hywel Dda
University Health Board

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
Planned Care	(0.3)	0.0	(0.3)	Non COVID-19: Planned Care is (£288k) better than forecast. Non pay is (£303k) better than forecast. Ophthalmology drug spend (£167k) less than forecast, due to a 15% reduction (150 injections) in patient numbers c.£75k, switch to Ongavia patients increased to 163 c.£50k & higher level of stock returns in month. Operating Theatres is (£117k) better than forecast due to lower than forecast orthopaedic procedures (32 less joints in PPH due to bed shortage on Ward 6, 16 less joints at BGH due to WAST strike action & colorectal infection control issues).
Mental Health & LD	(0.3)	0.0	(0.3)	Non COVID-19: Pay (170K)(60K) WG Funding Suicide + Self Harm Prevention Regional Co-ordinator 1 wte Band 7.(65K) Medical shift fill lower than forecast.(30K) RIF Funding Band 6 Nurse Progression Project. Non Pay (118K) (50K) CHC Packages 9 new, 8 ended,7 adjusted , 3 cease funded 1 not taken up and 3 under utilised releasing net savings.(45K) Premises and Fixed Plant Drop off Old accruals for Llanion House and Desk space at Ty Elwyn. (20K) General Supplies and services Drop off old accrual relating to Powys Invoice CAMHS Forensic Services.
Strategic Planning	(0.3)	0.0	(0.3)	Non COVID-19: Deviation to forecast is due to the release of the PWC PO (£200k) as this has been extended to Dec23 so will be incurred in 23-24. (£150k) improvement is due to the second phase of the PBC land/site appraisal work slipping into future months and into next financial year.

Month 10 EoY 2022/23: Key drivers (£'m)



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Hywel Dda
University Health Board



- Exceptional cost of Utilities assumed to be fully funded on a match basis to the value of £7.1m (Maximum funding capped based on Month 6 forecast at £7.5m).

Month 10 EoY 2022/23: Key drivers (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
Undelivered Savings	15.5	0.0	15.5	Non COVID-19: Undelivered planned savings across the Health Board.
USC GGH	6.7	0.0	6.7	Non COVID-19: Continuation of site pressures, especially on A&E with high levels of Nursing vacancies and use of surge beds are driving Nursing & HCSW cost pressures of £2.6m. Vacancies and Locum cover attribute to Medical & Dental overspends of £1.2m. Drugs overspend of £1k due to acuity and frailty of patients. Other Non-Pay of £1.2m is to due unfunded Pacemakers, Consumables, SLAs with BRC, and £113k of previous years undelivered savings.
Medicines Management	5.9	0.2	6.1	Non COVID-19: Overspend relates to Primary Care Prescribing with PARS projected overspend driven by items growth of 1.27%, price inflation in Baseline drugs, increased Category M prices as announced nationally for Q4 onwards & significant rising costs of NCSO drugs as inflation pushes drugs above the national tariff. COVID-19: Q1 prescribing costs attributed to regime changes resulting from Covid
USC WGH	4.7	1.3	6.0	Non COVID-19: Site pressures continue with 30 patients on discharge pathways, an average of 40 surge beds (35 in m9) with a peak of 47 (41 in m9) and an average of 24 patients in A&E needing a bed. As at 1st February we have 77 medically optimised patients against a bed base of 199. With staffing vacancies and premium cover driving Pay overspends in Medical £2,131k, and Nursing £1,050k, and with Non Pay overspend of £1,183k mainly as a result of Gastro Drugs overspend COVID-19: Driven by continued staffing of Puffin Ward through a mix of substantive and agency/bank staff.

Month 10 EoY 2022/23: Key drivers (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
USC PPH	4.7	0.5	5.2	<p>Non COVID-19: Continuation of site pressures and high levels of vacancies are driving Nursing and HCSW cost pressures of £0.9m. M&D £0.7m overspend, due to the historical funding shortfall against Consultants and increased locum costs covering sickness and vacancies. Previous Savings targets of £432k (bed closures not materialising). Non Pay overspends of £2.7m include £1.6m of Clinical Services and Supplies driven by high costs of Insulin Pumps and Consumables (mainly due to increased activities) and Drug overspends of £0.9m.</p> <p>COVID-19: COVID forecast driven by Pay £0.268m and Non Pay £0.258m. Pay mainly driven by Additional Clinical Services £0.090m, & Nursing & Midwifery £0.125m. Included in figures costs relate to the Acute Surge Capacity £0.108m against RN's and HCSW's. Non Pay overspend driven by Homecare drugs costs £0.258m.</p>
USC BGH	3.9	0.1	4.0	<p>Non COVID-19: EoY Forecast is driven by Pay pressures of £3.2m & Non Pay of £0.6m; Pay position reflects continued demand for beds and the surge into all beds/chairs/trolleys (average of 11 patients unplaced in ED) and increased high level of sickness & vacancies in Medical. Cost of drugs & supplies increasing with activity level and complexity of patients being admitted.</p> <p>COVID-19: Covid related costs for Red and Green pathways</p>
Oncology	3.3	0.2	3.5	<p>Non COVID-19: Significant overspend of £3.7m drug spend predicted driven by increased SACT activity of 30% (inc 9% 22/23) and costs 35% (inc 18% 22/23) since 2019/20 and continuing that upward trend, far in excess of current and prior years funding and now includes drug regime change cost impact made under covid from July. Chemocare maintenance and drugs transport spend also cost pressures but position partially offset by staffing vacancies (£444k) along with drug rebates, Macmillan and WHSCC income in excess of budget (£223k).</p> <p>COVID-19: Increased drugs costs due to guidance changes due to pandemic</p>

Month 10 EoY 2022/23: Key drivers (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
Facilities	1.7	1.8	3.5	<p>Non COVID-19: Income - expectation is (£2.2m) in excess of target for year due to laundry recharge (£1.7m) and BG rebates; Pay - expected overspend of £0.2m due to increased variable pay above budget mainly in 1st quarter due to double running from transfer of staff £470k, transfer of portering posts moved from COVID £250k, plus unfunded apprenticeships; Non pay - expectation is an overspend of £3.7m based on laundry charge £1.7m, utilities costs (unfunded) £640k, postage £600k, increased waste, materials and provision costs due to inflation c.£700k.</p> <p>COVID-19: Figure is made up of £1.28m worth of costs in regards to the enhanced cleaning programme; £240k of various remediation costs, including 1 wte maintenance engineer; £230k worth of pay costs for staffing in relation to service requests in Q1, now part of core, including additional porters.</p>
Reserves	(14.4)	0.8	(13.6)	<p>Non COVID-19: Central release of COVID-19 Annual leave accrual £(8.0)m, central Balance sheet releases and reserve slippage £(5.3)m, COVID-19 central adjustments £(0.8)m, pay enhancement on overtime release £(0.3)m.</p> <p>COVID-19: Recognition of central adjustments for COVID-19 sickness £0.4m, COVID-19 drugs £0.1m and central overtime enhancement provision £0.3m.</p>

Month 10 EoY 2022/23: Deviation from prior forecast (£'m)



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Hywel Dda
University Health Board



Note: Within the £1.4m reported as other directorate movements, £2.5m relates to the in month movement in risk mitigation.

Month 10 EoY 2022/23: Deviation from prior forecast (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
USC GGH	0.4	0.0	0.4	Non COVID-19: Pay increased by £365k. £265k due to in month number of substantive RNs increasing by 6.5 wte. Due to continuing system pressures, agency usage continues to increase with an additional 4.3 wte in month. These higher levels of both substantive & agency nursing are expected to continue (£55k), also a £210k increase due to the continuing issues around retro shifts and shifts worked but not yet invoiced. £67k HCSW - Increased Bank bookings of 9.63 wte (Teifi, Towy, Cadog & Y Lolfa) and continued onboarding costs of Overseas Nurse recruitment.
Oncology	0.4	0.0	0.4	Non COVID-19: January drugs spend was £243k higher than forecast, driven by 12% (233 patients) increase in activity against recent run rate average. This increased activity rate is now expected to continue for the remainder of the year increasing the end of year drugs overspend forecast by £390k. Homecare drugs catch up also seen in costs for December issues above that forecasted. Position improved slightly by increased estimate on drugs rebates and staff vacancies.
USC BGH	0.3	0.0	0.3	Non COVID-19: Deviation in forecast includes the recognition of increased medical locum shifts worked due to in the main increased medium term sickness and additional overnight support in ED (£200k); drugs has also increased in m10 due to increase of immune system drugs and this has been forecasted to continue (£52K); the forecast now reflects the risks around older nurse agency shifts worked not invoiced (£66k).
Primary Care	0.3	0.0	0.3	Non COVID-19: Adverse change against forecast driven by Community Pharmacy increased winter activity within Clinical Services from the Common Ailment Service (up 15%) and Flu (Up 5%) which support the pressures on GPs. Further impacted by under delivery of Dental Income (down 22%) against forecast and confirmation of commencement of Cluster projects (up 8%) previously classified as an amber risk and not within the forecast. Further impacted by GMS Enhanced Services (Drug driven Diabetes up) and Prescribing Drugs (up 9%)

Month 10 EoY 2022/23: Deviation from prior forecast (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
Mental Health	(0.4)	0.0	(0.4)	Non COVID-19: (175K) - Funding made available by WG, worked with Directorate to secure additional non -recurrent funding and badge against current spends.(55K) SMAFF Substance Misuse Team 4 wte Q4,(60K) for B7 Suicide Prevention Co-ordinator(30K) ""Active Response Team - currently recruiting for launch in May 23.(30K) B6 Nurse -Progression Project.(72K) (10wte) Vacancies main area's Nursing (4 wte) , HCSW (6 wte) across the Directorate.(50K) CHC Packages 9 new, 8 ended,7 adjusted , 3 cease funded 1 not taken up and 3 under utilised releasing net savings.(65K) Work carried out Reviewing old accruals resulted in Drop off for Llanion House and Desk space at Ty Elwyn and a Powys Invoice CAMHS Forensic Services.
Strategic Planning	(0.4)	0.0	(0.4)	Non COVID-19: The deviation to forecast is due to the release of the PWC PO (£200k) as this has been extended to Dec23 so will be incurred in 23-24. The balance is due to the second phase of the PBC land consultation work slipping into next financial year.
Planned Care	(0.5)	0.0	(0.5)	Non COVID-19: EOY forecast has improved by (£498k). This is driven by an improve't in the ophthal forecast of (£443k) largely due to reduced drugs spend. The in month movement is (£167k) driven by a red'n in the number of injections by 15% (150 injections) and the switch to lucentis biosimilar. The number of planned sessions in Feb and March are expected to deliver 300 less injections than previously forecast a reduction of circa £150k. The switch to the lucentis biosimilar is expected to deliver further savings of circa £100k over the remaining 2 months.
Reserves	(1.5)	0.0	(1.5)	Non COVID-19: Central release of Balance sheet items following review by FBP teams.

Month 10 EoY 2022/23: Risks

Risks	£'m	RAG
Oncology: drugs cost growth 5% increase	0.2	HL
Other < £0.2m	0.4	HL
Total highly likely	0.6	
MHLD: WG funding clawback ASD/recruitm't	0.8	P
Community Pharmacy underspend against ringfence	0.7	P
Meds Mgt: Drug rebate uncertainty	0.5	P
Meds Mgt: NCSO item number cont. Jan-Mar	0.5	P
Meds Mgt: Number of items exceed model	0.5	P
Microsoft SLA VAT rebate recovery	0.5	P
MHLD: CHC growth	0.4	P
Facilities: dispute with British Gas	0.3	P

Risks	£'m	RAG
Primary Care: Cluster c/f underspend	0.2	P
Dir Ops: Rate changes in OOH	0.2	P
Other <£0.2m	1.3	P
Total possible	5.9	
Total Risks	6.5	

Month 10 EoY 2022/23: Opportunities

Opportunities	£'m	RAG
Awaiting confirmation that WG may fund PBC land appraisal	(0.6)	HL
Transfer of costs associated with Nosocomial review	(0.2)	HL
Other <£0.2m	(0.0)	HL
Total highly likely	(0.8)	
Meds Mgt: Drug rebate uncertainty	(0.5)	P
Digital: Prior year VAT rebate Microsoft SLA	(0.3)	P
Planned Care: USC pressure impact elective	(0.3)	P
LTAs: Underperformance on English provider	(0.2)	P
Other <£0.2m	(0.2)	P
Total possible	(1.5)	P
Total Opportunities	(2.3)	

Forecast update

EoY Forecast £'m	Best case scenario	Moderate case scenario	Worst case scenario	Description
Updated Directorate forecast	60.2			All known control total adjustments have been realised/ mitigated.
Opportunity Programmes	0.0	0.0	0.0	Potential for improved forecast if programmes delivery in-year.
Issued control totals to directorates	(0.6)	(0.4)	0.0	
Review of year end liabilities	(0.0)	(0.0)	0.0	
Current identified risks	0.0	0.6	0.6	Oncology 5% patient increase £0.2m, other risks with an individual value of less than £0.2m £0.4m
Current identified opportunities	(0.6)	(0.6)	0.0	Potential WG funding for PBC land appraisal £(0.6)m.
Total Scenario/Choice Items	(1.2)	(0.4)	0.6	
Potential Reported deficit	59.0	59.8	60.8	

Choices and or actions previously taken	
Workforce: International Nurses initially was £0.7m, now only £0.4m	Health Board: Annual leave release, initially £8.0m, and enacted, in line with HR policy confirmation
Planned Care: Outsourcing initially £0.5m, now spent on internal WLIs	
Central Income: Powys LTA High Cost Drugs, initially £0.4m risk, now mitigated with agreement	
Primary Care: potential underspend, initially £2.0m, £1.9m delivered, but consumed with other spends	

Month 10 2022/23: Savings Performance and Identification

	Monthly Performance			Year to Date Performance			Annual 2022-23 & Full Year Effect			
Savings Delivery (£'000)	Mth Plan	Mth Act	Mth Var	YTD Plan	YTD Act	YTD Var	Year Plan	Year Act	Year Var	FYE Plan
Recurrent	176	171	4	1,480	1,462	18	1,831	1,805	26	2,409
FACILITIES	41	36	4	131	113	17	212	186	26	787
DIGITAL	52	52	0	515	515	0	619	619	0	622
MEDICINES MANAGEMENT	0	0	0	0	0	0	0	0	0	0
LTA'S WITH OTHER NHS PROVIDERS	83	83	0	834	833	1	1,001	1,001	(0)	1,001
Non Recurrent	1,187	1,187	0	10,215	10,215	0	12,061	12,061	0	0
HEALTH BOARD WIDE	1,187	1,187	0	10,180	10,180	0	12,026	12,026	0	0
FINANCE	0	0	0	35	35	0	35	35	0	0
Grand Total	1,363	1,359	4	11,695	11,677	18	13,893	13,866	26	2,409

Inefficiency activity drivers

Directorate	Demand	Supply			Configuration & Efficiency				Total
	RTL patients	Medical agency (premium)	Nursing agency (premium)	CHC	Medical y fit	Multiple sites (A&E and I/P)	Multiple sites (O/P)	Multiple sites (planned care)	
Unscheduled Care Configuration						16.6	0.8		17.4
Carmarthenshire	4.1		0.1						4.2
Ceredigion	2.9								2.9
Pembrokeshire	3.8		0.2						4.0
USC BGH		0.6	0.2		1.7				2.5
USC GGH		0.4	1.6		7.9				9.9
USC PPH		0.4	1.1		6.5				8.0
USC WGH		0.4	1.5		8.6				10.5
Women & Children		0.5	0.2						0.7
Planned care		1.2	0.8				0.7	1.1	3.8
MH & LD		0.3	0.9	10.0					11.2
Diagnostics								2.0	2.0
Operational pressures	10.8	3.7	7.5	10.0	24.7	16.6	1.5	3.1	77.1

This analysis sets out –at high level – the impact of demand, supply and configuration as drivers of our deficit.

Whilst some issues – such as supply issues in respect of premium pay for nurses and medical staff – are directly controllable, other areas are not

Configuration of service delivery is only partly controllable – such as where we locate some services

Executive Summary


	<p>Health Board's revised draft Financial Plan is to deliver a deficit of £62.0m, after savings of £13.9m; this recognises the inadequate level of assurance around the identification of a further £15.5m of savings schemes deliverable within the current financial year against our initial £25.0m deficit Plan, combined with an operational variation due to system pressures and continuation of COVID-19 activities within our core services.</p> <p>The forecast deficit is £59.0m, after recognising a further £5.0m of operational variation offset by £8.0m Accountancy Gains.</p>
Revenue	<ul style="list-style-type: none"> The Month 10 Health Board financial position is an overspend of £6.2m, which is made up of £4.1m operational variance and an original deficit plan of £2.1m; this is after recognising £0.3m of WG transitional funding for COVID-19. £1.4m of savings schemes were delivered in line with identified plans. Of the £4.1m overspend in-month, £1.1m relates to undelivered savings plans against the original target and £3.0m relates to operational pressures. These pressures are mainly being experienced within our Unscheduled Care teams, but also within Medicines Management in relation to Primary Care Prescribing and in Oncology due to increased activity.
Projection	<ul style="list-style-type: none"> The Health Board has received confirmation of WG funding to match the costs of the COVID-19 programmes (Tracing, Testing, Mass Vaccinations and PPE), and also to match the costs of the COVID-19 Transitional Responses and Exceptional Energy up to a maximum of the Month 8 and 6 forecast respectively. WG funding has been received in respect of the Health and Social Care Levy, Exceptional Real Living Wage commissioned costs and the Pay Award. Since our initial plan submission, each Executive Director and their respective leadership teams have been reviewing their operational plans to deliver a step change through targeted programmes of work. Trajectories are being developed, but as yet limited assurance can be taken for in-year financial benefit realisation. This represents a significant concern with regards to the underlying deficit into the new financial year.
Savings	<ul style="list-style-type: none"> Of the identified operational savings schemes of £13.9m, only a small number are currently assessed as recurrent, with a full year effect of £2.0m. This is contributing to the deterioration in the underlying deficit to £80.0m from the brought forward 2021/22 position of £68.9m, which presents a challenge to be addressed as part of our targeted programmes of work. In addition to the operational schemes, a non-recurrent Accountancy Gain of £8.0m has been identified in relation to the part release of an Annual Leave carryover provision following Workforce Policy confirmation.
Next Steps	<ul style="list-style-type: none"> The Health Board is working through the Targeted Intervention Framework under the four key themes of: 1) Analysis of the drivers from a £25.0m deficit to a £67.0m deficit; 2) Continuous development and implementation of the Opportunities framework; 3) Organisation's Delivery framework; 4) Review of financial management arrangements. As a result of the analysis of the deficit drivers, it is expected that the assessment of the underlying deficit will show a deterioration from £80.0m to a worst case scenario of £94.7m; this is being taken through the Board governance process before formalising. Engaging with the organisation on plans for the coming year. Further development of Improving Together framework, Integrated finance and performance Directorate management meetings.

Executive Summary

Summary of key financial targets					
<p>The Health Board's key targets are as follows:</p> <ul style="list-style-type: none"> Revenue: to contain the overspend within the Health Board's planned deficit Savings: to deliver savings plans to enable the revenue budget to be achieved Capital: to contain expenditure within the agreed limit PSPP: to pay 95% of Non-NHS invoices within 30 days of receipt of a valid invoice Cash: While there is no prescribed limit for cash held at the end of the month, WG encourages this to be minimised and a rule of thumb of 5% of monthly expenditure is used. For the Health Board, this is broadly £4.0m. 					
Key target		Annual limit	YTD limit	Actual delivery	Forecast Risk
Revenue	£'m	59.0	46.2	46.4	Medium*
Savings	£'m	21.9	19.7	19.7	Low**
Capital	£'m	33.2	18.6	18.6	Low
Non-NHS PSPP	%	95.0	95.0	95.0	Low***
Period end cash	£'m	4.0	4.0	2.4	Low****
<p>* The Health Board is forecasting a financial outturn position of £59.0m, which is an improvement against the re-submitted draft annual plan of £62.0m, which is £34.0m higher than the previous planned deficit of £25.0m. Whilst the delivery risk to the revised forecast deficit of £59.0m is considered to be Low, this is an unacceptable level of deficit and urgent management actions are required to address the underlying position; given the expected worsening of the underlying position due to pressures, particularly in Unscheduled Care, Primary Care Prescribing and drugs, the risk has been escalated to Medium given the trajectory.</p> <p>** Of the identified operational savings schemes of £13.9m, only a small number are currently assessed as recurrent, with a full year effect of £2.0m. This is contributing to the deterioration in the underlying deficit to £80.0m from the brought forward 2021/22 position of £68.9m, which presents a challenge to be addressed as part of our 2023/24 planning cycle. In addition to the operational schemes, a non-recurrent Accountancy Gain of £8.0m has been identified in relation to the part release of an Annual Leave carryover provision.</p> <p>***The Health Board has now achieved its PSPP target of paying 95% of its non-NHS invoices within 30 days in Quarter 3, and the cumulative position at Month 10 is 95.2%. There remains a Low risk, given the failure in Quarter 2 (93.6%) caused by delays in authorising invoices by the service and the remaining concern due to staff shortages within specific areas. Work continues to support process improvements to further improve the cumulative position.</p> <p>**** WG have confirmed that Strategic Cash funding will be made available in line with the Health Board's request to fund the cash consequences of the revenue deficit.</p>					

Revenue Summary


YTD variance by Directorate (against Plan)



Key drivers of YTD position


- **Savings non delivery £12.8m:** YTD value of savings undelivered by the organisation (against the original Plan of £29.4m).
- **Unscheduled care £17.5m:** Continuation of site pressures where high levels of vacancies and activity are resulting in high variable pay expenditure across all four acute sites.
- **Radiology £2.7m:** Workforce pressures due to vacancies and sickness resulting in high variable pay expenditure and outsourcing of services from private providers across all four acute sites.
- **Facilities £3.6m:** Overspends are driven in core areas by the increasing cost of utilities and provisions and the loss of revenue in canteens and external vendors. COVID-19 expenditure relates to on-going expenditure in relation to enhanced cleaning standards and remedial works to Health Board estate.
- **Medicines Management £5.8m:** Baseline price increases and volume growth in Prescribing with significant increases in NCSO and Category M drugs specifically.
- **Public Health £9.8m:** Primarily driven by costs associated with the Health Board's on-going response to COVID-19 in regards to TTP and Mass Vaccinations.
- **WG Programme Funding £(11.0)m:** YTD funding in respect of COVID-19 programme schemes has been included in the position.
- **WG Transitional Funding £(6.3)m:** YTD funding has been to match transitional support costs in line with the Health Board's plan to exit, wherever possible, COVID-19 specific activities.
- **WG Other funding £(2.4)m:** Fixed allocation funding to support COVID-19 response for various schemes.

YTD actual by Directorate (COVID-19 only)




Revenue Summary

YTD variance by Subjective (against Plan)




YTD actual by Subjective (COVID-19 only)



Key drivers of YTD position

- **Savings non delivery £12.8m:** YTD value of savings undelivered by the organisation (against the original Plan of £29.4m).
- **Pay £23.6m:** Continued high levels of variable pay expenditure across various staff groups due to high levels of vacancies across the Health Board and on-going pressures in Unscheduled Care. Continued COVID-19 pay expenditure is primarily supporting the Health Board's response in respect of TTP, Mass Vaccination and enhanced cleaning standards.
- **Drugs £7.8m:** Activity and price growth in Oncology, Homecare drugs and Scheduled Care following changes in clinical guidelines and increased activity following COVID-19. There has also been a higher than average increase in Unscheduled Care drugs expenditure as Emergency Departments continue to experience unprecedented demand.
- **Income £(8.1)m:** Primarily driven by the recognition of Value Based Healthcare funding offset by consultancy charges. In addition, receipt of British Gas rebates for prior period CHP underperformance and higher than anticipated income for the Education Service liaison and in relation to non contracted activity.
- **Premises & Plant £3.9m:** Primarily driven by remedial work to Health Board estate and IT infrastructure costs.
- **Accountancy gains £(8.0)m:** Month 8 recognition of the impact of the Workforce National Policy revision to Annual Leave carryover provision.



Key Subjective Summary




Key Subjective Summary

<div>CHC</div> <div><table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>4.2</td><td>4.1</td></tr><tr><td>P02-22</td><td>4.4</td><td>4.3</td></tr><tr><td>P03-22</td><td>4.7</td><td>4.6</td></tr><tr><td>P04-22</td><td>4.5</td><td>4.4</td></tr><tr><td>P05-22</td><td>4.1</td><td>4.0</td></tr><tr><td>P06-22</td><td>5.0</td><td>4.9</td></tr><tr><td>P07-22</td><td>4.5</td><td>4.4</td></tr><tr><td>P08-22</td><td>4.4</td><td>4.3</td></tr><tr><td>P09-22</td><td>4.5</td><td>4.4</td></tr><tr><td>P10-22</td><td>4.7</td><td>4.6</td></tr><tr><td>P11-22</td><td>4.2</td><td>4.1</td></tr><tr><td>P12-22</td><td>3.9</td><td>3.8</td></tr><tr><td>P01-23</td><td>4.2</td><td>4.1</td></tr><tr><td>P02-23</td><td>4.3</td><td>4.2</td></tr><tr><td>P03-23</td><td>4.2</td><td>4.1</td></tr><tr><td>P04-23</td><td>4.3</td><td>4.2</td></tr><tr><td>P05-23</td><td>5.5</td><td>5.4</td></tr><tr><td>P06-23</td><td>4.5</td><td>4.4</td></tr><tr><td>P07-23</td><td>4.6</td><td>4.5</td></tr><tr><td>P08-23</td><td>4.5</td><td>4.4</td></tr><tr><td>P09-23</td><td>5.2</td><td>5.1</td></tr><tr><td>P10-23</td><td>4.2</td><td>4.1</td></tr><tr><td>P11-23</td><td>4.2</td><td>4.1</td></tr><tr><td>P12-23</td><td>4.6</td><td>4.5</td></tr></table></div>	Period	Actual expenditure	Budgeted expenditure	P01-22	4.2	4.1	P02-22	4.4	4.3	P03-22	4.7	4.6	P04-22	4.5	4.4	P05-22	4.1	4.0	P06-22	5.0	4.9	P07-22	4.5	4.4	P08-22	4.4	4.3	P09-22	4.5	4.4	P10-22	4.7	4.6	P11-22	4.2	4.1	P12-22	3.9	3.8	P01-23	4.2	4.1	P02-23	4.3	4.2	P03-23	4.2	4.1	P04-23	4.3	4.2	P05-23	5.5	5.4	P06-23	4.5	4.4	P07-23	4.6	4.5	P08-23	4.5	4.4	P09-23	5.2	5.1	P10-23	4.2	4.1	P11-23	4.2	4.1	P12-23	4.6	4.5	<p>Continuing Health Care expenditure has increased by £0.3m compared to last month.</p> <p>A general reduction in packages has been noted across general CHC within the locality, however this has been offset by a net increase of clients within Mental Health along with a number of adjusted packages due to acuity.</p>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	4.2	4.1																																																																										
P02-22	4.4	4.3																																																																										
P03-22	4.7	4.6																																																																										
P04-22	4.5	4.4																																																																										
P05-22	4.1	4.0																																																																										
P06-22	5.0	4.9																																																																										
P07-22	4.5	4.4																																																																										
P08-22	4.4	4.3																																																																										
P09-22	4.5	4.4																																																																										
P10-22	4.7	4.6																																																																										
P11-22	4.2	4.1																																																																										
P12-22	3.9	3.8																																																																										
P01-23	4.2	4.1																																																																										
P02-23	4.3	4.2																																																																										
P03-23	4.2	4.1																																																																										
P04-23	4.3	4.2																																																																										
P05-23	5.5	5.4																																																																										
P06-23	4.5	4.4																																																																										
P07-23	4.6	4.5																																																																										
P08-23	4.5	4.4																																																																										
P09-23	5.2	5.1																																																																										
P10-23	4.2	4.1																																																																										
P11-23	4.2	4.1																																																																										
P12-23	4.6	4.5																																																																										
<div>Secondary Care Drugs</div> <div><table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>4.0</td><td>3.8</td></tr><tr><td>P02-22</td><td>4.2</td><td>3.9</td></tr><tr><td>P03-22</td><td>3.7</td><td>3.8</td></tr><tr><td>P04-22</td><td>4.1</td><td>3.8</td></tr><tr><td>P05-22</td><td>3.9</td><td>3.8</td></tr><tr><td>P06-22</td><td>4.3</td><td>3.8</td></tr><tr><td>P07-22</td><td>4.2</td><td>4.0</td></tr><tr><td>P08-22</td><td>4.5</td><td>4.0</td></tr><tr><td>P09-22</td><td>4.4</td><td>4.0</td></tr><tr><td>P10-22</td><td>4.3</td><td>4.0</td></tr><tr><td>P11-22</td><td>4.0</td><td>4.0</td></tr><tr><td>P12-22</td><td>4.5</td><td>4.0</td></tr><tr><td>P01-23</td><td>4.0</td><td>3.9</td></tr><tr><td>P02-23</td><td>4.5</td><td>4.0</td></tr><tr><td>P03-23</td><td>4.2</td><td>3.9</td></tr><tr><td>P04-23</td><td>4.0</td><td>3.9</td></tr><tr><td>P05-23</td><td>4.7</td><td>3.9</td></tr><tr><td>P06-23</td><td>5.0</td><td>4.3</td></tr><tr><td>P07-23</td><td>5.3</td><td>4.4</td></tr><tr><td>P08-23</td><td>5.3</td><td>4.3</td></tr><tr><td>P09-23</td><td>3.4</td><td>2.8</td></tr><tr><td>P10-23</td><td>5.2</td><td>3.9</td></tr><tr><td>P11-23</td><td>3.9</td><td>3.9</td></tr><tr><td>P12-23</td><td>3.9</td><td>3.9</td></tr></table></div>	Period	Actual expenditure	Budgeted expenditure	P01-22	4.0	3.8	P02-22	4.2	3.9	P03-22	3.7	3.8	P04-22	4.1	3.8	P05-22	3.9	3.8	P06-22	4.3	3.8	P07-22	4.2	4.0	P08-22	4.5	4.0	P09-22	4.4	4.0	P10-22	4.3	4.0	P11-22	4.0	4.0	P12-22	4.5	4.0	P01-23	4.0	3.9	P02-23	4.5	4.0	P03-23	4.2	3.9	P04-23	4.0	3.9	P05-23	4.7	3.9	P06-23	5.0	4.3	P07-23	5.3	4.4	P08-23	5.3	4.3	P09-23	3.4	2.8	P10-23	5.2	3.9	P11-23	3.9	3.9	P12-23	3.9	3.9	<p>Secondary Care Drug expenditure has increased by £1.8m in-month compared to last.</p> <p>The increase in expenditure is primarily due to a 12% increase in SACT activity within Oncology compared to the forecasted run rate alongside a 9% increase in Haematology drugs during the month as services return following the Christmas period.</p> <p>Homecare drug expenditure has also increased in-month partially due to a 'catch up' from the Christmas period and the continued pressures within A&E resulting in continued increases in drug expenditure.</p>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	4.0	3.8																																																																										
P02-22	4.2	3.9																																																																										
P03-22	3.7	3.8																																																																										
P04-22	4.1	3.8																																																																										
P05-22	3.9	3.8																																																																										
P06-22	4.3	3.8																																																																										
P07-22	4.2	4.0																																																																										
P08-22	4.5	4.0																																																																										
P09-22	4.4	4.0																																																																										
P10-22	4.3	4.0																																																																										
P11-22	4.0	4.0																																																																										
P12-22	4.5	4.0																																																																										
P01-23	4.0	3.9																																																																										
P02-23	4.5	4.0																																																																										
P03-23	4.2	3.9																																																																										
P04-23	4.0	3.9																																																																										
P05-23	4.7	3.9																																																																										
P06-23	5.0	4.3																																																																										
P07-23	5.3	4.4																																																																										
P08-23	5.3	4.3																																																																										
P09-23	3.4	2.8																																																																										
P10-23	5.2	3.9																																																																										
P11-23	3.9	3.9																																																																										
P12-23	3.9	3.9																																																																										

Key Subjective Summary

<h3>Clinical Supplies and Services</h3>  <table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>2.6</td><td>2.6</td></tr><tr><td>P02-22</td><td>2.6</td><td>2.7</td></tr><tr><td>P03-22</td><td>3.0</td><td>2.9</td></tr><tr><td>P04-22</td><td>3.4</td><td>3.0</td></tr><tr><td>P05-22</td><td>3.4</td><td>2.9</td></tr><tr><td>P06-22</td><td>3.0</td><td>3.4</td></tr><tr><td>P07-22</td><td>2.7</td><td>2.9</td></tr><tr><td>P08-22</td><td>3.0</td><td>2.7</td></tr><tr><td>P09-22</td><td>3.8</td><td>2.9</td></tr><tr><td>P10-22</td><td>5.2</td><td>4.3</td></tr><tr><td>P11-22</td><td>3.5</td><td>3.4</td></tr><tr><td>P12-22</td><td>5.6</td><td>3.9</td></tr><tr><td>P01-23</td><td>3.0</td><td>2.8</td></tr><tr><td>P02-23</td><td>3.2</td><td>3.1</td></tr><tr><td>P03-23</td><td>3.1</td><td>3.0</td></tr><tr><td>P04-23</td><td>3.4</td><td>3.1</td></tr><tr><td>P05-23</td><td>3.1</td><td>2.9</td></tr><tr><td>P06-23</td><td>3.3</td><td>3.1</td></tr><tr><td>P07-23</td><td>3.2</td><td>3.0</td></tr><tr><td>P08-23</td><td>3.4</td><td>3.0</td></tr><tr><td>P09-23</td><td>3.4</td><td>3.0</td></tr><tr><td>P10-23</td><td>2.7</td><td>3.0</td></tr><tr><td>P11-23</td><td>2.8</td><td>2.9</td></tr><tr><td>P12-23</td><td>2.9</td><td>2.9</td></tr></table>	Period	Actual expenditure	Budgeted expenditure	P01-22	2.6	2.6	P02-22	2.6	2.7	P03-22	3.0	2.9	P04-22	3.4	3.0	P05-22	3.4	2.9	P06-22	3.0	3.4	P07-22	2.7	2.9	P08-22	3.0	2.7	P09-22	3.8	2.9	P10-22	5.2	4.3	P11-22	3.5	3.4	P12-22	5.6	3.9	P01-23	3.0	2.8	P02-23	3.2	3.1	P03-23	3.1	3.0	P04-23	3.4	3.1	P05-23	3.1	2.9	P06-23	3.3	3.1	P07-23	3.2	3.0	P08-23	3.4	3.0	P09-23	3.4	3.0	P10-23	2.7	3.0	P11-23	2.8	2.9	P12-23	2.9	2.9	<p>Clinical supply and service expenditure has reduced by £0.7m in-month.</p> <p>The reduction in clinical services and supplies has been driven by a lower than planned number of Orthopaedic procedures due to bed shortages and WAST industrial action.</p> <p>This reduction has been compounded by lower expenditure than previous months on diabetic pump consumables and the release of a number of maintenance contracts following an FBP risk adjusted review of invoices being recognised.</p>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	2.6	2.6																																																																										
P02-22	2.6	2.7																																																																										
P03-22	3.0	2.9																																																																										
P04-22	3.4	3.0																																																																										
P05-22	3.4	2.9																																																																										
P06-22	3.0	3.4																																																																										
P07-22	2.7	2.9																																																																										
P08-22	3.0	2.7																																																																										
P09-22	3.8	2.9																																																																										
P10-22	5.2	4.3																																																																										
P11-22	3.5	3.4																																																																										
P12-22	5.6	3.9																																																																										
P01-23	3.0	2.8																																																																										
P02-23	3.2	3.1																																																																										
P03-23	3.1	3.0																																																																										
P04-23	3.4	3.1																																																																										
P05-23	3.1	2.9																																																																										
P06-23	3.3	3.1																																																																										
P07-23	3.2	3.0																																																																										
P08-23	3.4	3.0																																																																										
P09-23	3.4	3.0																																																																										
P10-23	2.7	3.0																																																																										
P11-23	2.8	2.9																																																																										
P12-23	2.9	2.9																																																																										
<h3>Primary Care Prescribing</h3>  <table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>6.0</td><td>5.8</td></tr><tr><td>P02-22</td><td>5.7</td><td>5.5</td></tr><tr><td>P03-22</td><td>6.5</td><td>6.2</td></tr><tr><td>P04-22</td><td>6.5</td><td>6.1</td></tr><tr><td>P05-22</td><td>6.0</td><td>5.8</td></tr><tr><td>P06-22</td><td>6.4</td><td>6.1</td></tr><tr><td>P07-22</td><td>6.5</td><td>6.4</td></tr><tr><td>P08-22</td><td>6.4</td><td>6.4</td></tr><tr><td>P09-22</td><td>6.4</td><td>6.4</td></tr><tr><td>P10-22</td><td>5.8</td><td>5.8</td></tr><tr><td>P11-22</td><td>5.6</td><td>5.6</td></tr><tr><td>P12-22</td><td>6.6</td><td>6.3</td></tr><tr><td>P01-23</td><td>6.2</td><td>6.1</td></tr><tr><td>P02-23</td><td>6.1</td><td>6.1</td></tr><tr><td>P03-23</td><td>6.2</td><td>6.1</td></tr><tr><td>P04-23</td><td>6.4</td><td>6.1</td></tr><tr><td>P05-23</td><td>6.1</td><td>6.1</td></tr><tr><td>P06-23</td><td>7.2</td><td>6.1</td></tr><tr><td>P07-23</td><td>6.7</td><td>6.1</td></tr><tr><td>P08-23</td><td>7.1</td><td>6.1</td></tr><tr><td>P09-23</td><td>8.0</td><td>6.1</td></tr><tr><td>P10-23</td><td>7.0</td><td>6.1</td></tr><tr><td>P11-23</td><td>6.5</td><td>6.5</td></tr><tr><td>P12-23</td><td>6.5</td><td>6.5</td></tr></table>	Period	Actual expenditure	Budgeted expenditure	P01-22	6.0	5.8	P02-22	5.7	5.5	P03-22	6.5	6.2	P04-22	6.5	6.1	P05-22	6.0	5.8	P06-22	6.4	6.1	P07-22	6.5	6.4	P08-22	6.4	6.4	P09-22	6.4	6.4	P10-22	5.8	5.8	P11-22	5.6	5.6	P12-22	6.6	6.3	P01-23	6.2	6.1	P02-23	6.1	6.1	P03-23	6.2	6.1	P04-23	6.4	6.1	P05-23	6.1	6.1	P06-23	7.2	6.1	P07-23	6.7	6.1	P08-23	7.1	6.1	P09-23	8.0	6.1	P10-23	7.0	6.1	P11-23	6.5	6.5	P12-23	6.5	6.5	<p>Primary Care Prescribing costs have decreased by £1.0m in-month.</p> <p>This is due to the return to Month 8 levels following the Month 9 recognition of YTD growth and unprecedented increased in the number of concessionary prices granted for the month of December within the No Cheaper Source Obtainable (NCSO) drug list, partly driven by the addition of a number of antibiotics.</p> <p>The Month 10 position recognises continued item growth at the Month 9 levels, within both Baseline and Category M drugs and inflated prices for antibiotics (which is likely to be due to the impact of Strep A); within Category M drugs, there were 14 antibiotics which would normally have cost the set Drug Tariff price.</p>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	6.0	5.8																																																																										
P02-22	5.7	5.5																																																																										
P03-22	6.5	6.2																																																																										
P04-22	6.5	6.1																																																																										
P05-22	6.0	5.8																																																																										
P06-22	6.4	6.1																																																																										
P07-22	6.5	6.4																																																																										
P08-22	6.4	6.4																																																																										
P09-22	6.4	6.4																																																																										
P10-22	5.8	5.8																																																																										
P11-22	5.6	5.6																																																																										
P12-22	6.6	6.3																																																																										
P01-23	6.2	6.1																																																																										
P02-23	6.1	6.1																																																																										
P03-23	6.2	6.1																																																																										
P04-23	6.4	6.1																																																																										
P05-23	6.1	6.1																																																																										
P06-23	7.2	6.1																																																																										
P07-23	6.7	6.1																																																																										
P08-23	7.1	6.1																																																																										
P09-23	8.0	6.1																																																																										
P10-23	7.0	6.1																																																																										
P11-23	6.5	6.5																																																																										
P12-23	6.5	6.5																																																																										

Financial Projection



Key Assumptions

- The direct impact of COVID-19, including programme expenditure (in respect of mass vaccination programmes, Testing, Tracing, and PPE) is modelled up to a twelve-month scenario.
- All WG COVID-19 and Exceptional Costs (Energy and Real Living Wage commissioned services) funding is based on the current forecast costs on a match-basis (capped at a maximum of the Month 6 financial forecast).
- The impact of the in-year operational cost pressures in excess of the original plan will be fully reviewed as part of the Planning Cycle for 2023/24 to determine the opening Underlying Deficit.
- Any backfill costs of staff utilising carried forward Annual Leave during the year is assumed to be within the current run rate.
- No financial impact is assumed as a result of industrial action, with work underway through our Action Group.

Assurance

- Executive led Use of Resources Group which scrutinises business cases, opportunities and financial governance.
- Performance to continue to be monitored monthly through robust Directorate Use of Resources meetings.


Concerns

- There has been a net deterioration in the underlying deficit of £68.9m in 2021/22 to the current assessment for 2022/23 of £80.0m, which was not the expected outcome of the revised planning cycle during Quarter 1 and subsequent months.
- Whilst the forecast deficit has improved from £62.0m to £59.0m this recognises an additional £5.0m of operational variation offset by £8.0m of non-recurrent Accountancy Gains.

Next Steps

- The Health Board is working through the Targeted Intervention Framework under the four key themes of: 1) Analysis of the drivers from a £25.0m deficit to a £67.0m deficit; 2) Continuous development and implementation of the Opportunities framework; 3) Organisation's Delivery framework; 4) Review of financial management arrangements.
- As a result of the analysis of the deficit drivers, it is expected that the assessment of the underlying deficit will show a deterioration from £80.0m to a worst case scenario of £94.7m; this is being taken through the Board governance process before formalising.
- Engaging with the organisation on plans for the coming year.
- Further development of the new Improving Together framework, Integrated finance and performance Directorate management meetings, which commenced on 30th January 2023.
- A weekly progress report is being presented to the Executive Team to retain sufficient strategic focus on key deliverables.

Risk-assessed directorate savings profile, delivery and forecast



Assurance

- Of the original £29.4m requirement, £13.9m have been identified as operational Green schemes, as a minimum on a non-recurrent basis; in addition to this £8.0m of Accountancy Gains have been recognised in Month 8 which is not included in the above graph which presents the £13.9m of operational delivery schemes only. All schemes are assessed as Green.
- The Plan re-submission is aligned to delivery of the identified savings schemes of £12.4m. Since the Plan, a further £1.5m recurrent Green schemes have been identified.
- In-month delivery of £1.4m, which is in line with the Green savings scheme plans.

Concerns

- Whilst the focus of the Health Board is on identifying and implementing recurrent schemes, the current combination of capacity and system pressures being experienced operationally has diverted significant managerial resource. This has meant that, of the original required £29.4m, only £13.9m of operational schemes have been identified, largely on a non-recurrent basis. The £8.0m Accountancy Gain is also a non-recurrent benefit.
- The Executive led targeted programmes of work trajectories are being developed, but as yet no assurance can be taken for the in-year or future year financial benefit realisation.

Next Steps

- Having the clarity of the opportunities has enabled the team to buy into the areas that need to be influenced and changed, but we are yet to agree and have sight of detailed plans that illustrate a clear route to delivery through our planning framework.
- The Board recognise the need to develop opportunities for change through Use of Resources groups (Directorate level and Executive Level) as a matter of urgency.
- Collaborative dialogue with WG and FDU is continuing with the Health Board in support of progressing the agreed TI workstream deliverables.

This Table is currently showing 0 errors

Line 14 should reflect the corresponding amounts included within the latest MTP/AOP submission to WG
Lines 1 - 14 should not be adjusted after Month 1

	In Year Effect	Non Recurring	Recurring	FYE of Recurring
	£'000	£'000	£'000	£'000
1 Underlying Position bnfed from Previous Year - must agree to M12 MMR (Deficit - Negative Value)	-68,888	0	-68,888	-68,888
2 Planned New Expenditure (Non Covid-19) (Negative Value)	-67,224	-3,762	-59,462	-62,008
3 Planned Expenditure For Covid-19 (Negative Value)	-23,196	-23,196	0	0
4 Planned Welsh Government Funding (Non Covid-19) (Positive Value)	61,746	7,792	53,954	61,746
5 Planned Welsh Government Funding for Covid-19 (Positive Value)	23,196	23,196	0	0
6 Planned Capital Income (Positive Value)	0	0	0	0
7 RRL Profile - Planning only (In Year Effect / Column C must be nil)	0	0	0	0
8 Planned (Finalised) Savings Plan	12,366	12,061	305	487
9 Planned (Finalised) Net Income Generation	0	0	0	0
10 Planned Profit / (Loss) on Disposal of Assets	0	0	0	0
11 Planned Release of Uncommitted Contingencies & Reserves (Positive Value)	0	0	0	0
12	0	0	0	0
13 Planning Assumptions still to be finalised at Month 1	0	0	0	0
14 Opening MTP - Annual Operating Plan	-62,000	12,061	-74,061	-76,005
15 Reversal of Planning Assumptions still to be finalised at Month 1	0	0	0	0
16 Additional In Year & Movement from Planned Release of Previously Committed Contingencies & Reserves (Positive Value)	0	0	0	0
17 Additional In Year & Movement from Planned Profit / (Loss) on Disposal of Assets	0	0	0	0
18 Other Movement in Month 1 Planned & In Year Net Income Generation	1,000	0	1,000	1,000
19 Overschachievement - (Underachievement) /	0	0	0	0
20 Additional In Year Identified Savings - Forecast	489	0	489	489
21 Variance to Planned RRL & Other Income	0	0	0	0
22 Additional In Year & Movement in Planned Welsh Government Funding for Covid-19 (Positive Value - additional)	-874	-874	0	0
23 Additional In Year & Movement in Planned Welsh Government Funding (Non Covid) (Positive Value - additional)	0	0	0	0
24 Additional In Year & Movement Expenditure for Covid-19 (Negative Value - additional) (Positive Value - reduction)	874	874	0	0
25 In Year Accounting Gains (Positive Value)	8,000	8,000	0	0
26 Net In Year Operational Variance to MTP/AOP (material gross amounts to be listed separately)	0	0	0	0
27 Unchecked/and Care and Facilities and Radiology operational pressures	36	36	0	0
28 Unidentified savings to mitigate operational pressures	-36	-36	0	0
29	-3,500	-1,495	-2,500	-2,500
30	-900	0	-900	-900
31	-500	0	-500	-500
32	-2,087	-1,887	-200	-200
33	-900	0	-900	-900
34	326	326	0	0
35	1,561	1,561	0	0
36 Forecast Outturn (- Deficit / + Surplus)	-59,000	16,672	-77,672	-80,816
41 Covid-19 - Forecast Outturn (- Deficit / + Surplus)	0	0	0	0
42 Operational - Forecast Outturn (- Deficit / + Surplus)	-59,000	0	0	0

	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	YTD	In Year Effect
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
1	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-57,407	-68,888
2	-4,884	-4,541	-4,260	-5,230	-5,701	-6,038	-6,129	-6,140	-6,123	-6,141	-5,823	-6,233	-55,187	-67,224
3	-2,906	-3,312	-2,239	-1,815	-1,496	-1,853	-1,702	-1,862	-1,896	-1,894	-1,823	-1,638	-20,135	-23,196
4	5,146	5,146	5,146	5,146	5,146	5,146	5,146	5,146	5,146	5,146	5,146	5,146	51,465	61,746
5	2,806	3,312	2,239	1,815	1,496	1,853	1,702	1,862	1,896	1,894	1,823	1,638	20,135	23,196
6	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8	1,013	869	1,652	1,075	743	748	1,319	1,004	789	1,229	803	1,022	10,440	12,366
9	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0	0	0	0	0	0
14	-4,446	-4,268	-3,204	-4,690	-6,256	-6,023	-6,406	-6,731	-6,817	-6,261	-6,164	-6,485	-60,679	-62,000
15	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	500	83	83	83	83	83	83	833	1,000
19	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	245	41	41	41	41	41	41	408	489
21	0	0	0	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	119	-230	23	187	11	72	-621	-236	-199	-439	-874
23	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24	0	0	0	-119	230	-23	-187	-11	-72	621	236	199	439	874
25	0	0	0	0	0	0	0	8,000	0	0	0	0	8,000	8,000
26	0	0	0	59	-7	-7	-7	-7	-7	-7	-7	-9	17	0
27	0	0	0	0	0	0	0	0	0	0	0	36	0	36
28	0	0	0	0	0	0	0	0	0	0	0	-36	0	-36
29	0	0	0	0	-696	-874	-724	-558	-571	-308	-162	-195	-3,632	-3,500
30	0	0	0	0	0	0	0	-40	-40	-274	-273	-273	-354	-900
31	0	0	0	0	0	0	0	0	0	-167	-165	-167	-167	-500
32	0	0	0	0	0	0	0	-40	-1,346	-313	-262	-266	-1,699	-2,087
33	0	0	0	0	0	0	0	-180	-180	-180	-180	-180	-540	-900
34	0	0	0	0	0	0	0	0	0	107	109	110	107	326
35	0	0	0	0	0	0	0	0	0	1132	122	148	129	1,561
36	-4,446	-4,268	-3,204	-4,690	-6,256	-6,023	-6,406	-6,731	-6,817	-6,261	-6,164	-6,485	-60,679	-62,000
37	0	0	0	0	0	0	0	0	0	0	0	0	0	0
38	-4,446	-4,268	-3,204	-4,690	-6,256	-6,023	-6,406	-6,731	-6,817	-6,261	-6,164	-6,485	-60,679	-62,000

Table A1 - Underlying Position

Section A - By Spend Area		Full Year Effect of Actions		Subtotal	Net Year Effect of Undigested Demand (€m)	IMTP Underlying Position of
		Underlying Position of	Recurring Savings (€m)			
	€'000	€'000	Recurring Allocations (Income) (€m)	€'000	€'000	€'000
1 Pay - Administration, Clinical & Board Members	(264)			(264)	(260)	(1,184)
2 Pay - Medical & Dental	(10,496)			(10,496)	3,430	(7,066)
3 Pay - Nursing & Midwifery Registered	(6,542)			(6,542)	(4,083)	(2,459)
4 Pay - Prof Scientific & Technical	(1,814)			(1,814)	500	(814)
5 Pay - Additional Clinical Services	(1,110)			(1,110)	3,405	(1,110)
6 Pay - Allied Health Professionals	1,874			1,874	(101)	1,773
7 Pay - Healthcare Specialists	99			99	0	99
8 Pay - Estates & Facilities	25			25	(207)	(182)
9 Pay - Students	0			0	0	0
10 Non Pay - Supplies and services - clinical	(12,140)			(12,140)	(10,907)	(22,801)
11 Non Pay - Supplies and services - general	(1,419)			(1,419)	(8,211)	(9,630)
12 Non Pay - Consumables Services	(812)			(812)	0	(812)
13 Non Pay - Entertainment	(993)			(993)	(100)	(1,480)
14 Non Pay - Transport	(1,129)			(1,129)	0	(1,129)
15 Non Pay - Premises	(4,118)			(4,118)	0	(4,079)
16 Non Pay - External Contractors	(1,889)			(1,889)	(100)	(2,489)
17 Health Care Provided by other Orgs - Welsh LHBs	(5,197)			(5,197)	1,000	(1,197)
18 Health Care Provided by other Orgs - Welsh Trusts	(1,738)			(1,738)	0	(1,738)
19 Health Care Provided by other Orgs - NHS/SC	(12,268)			(12,268)	0	(12,268)
20 Health Care Provided by other Orgs - English	0			0	0	0
21 Health Care Provided by other Orgs - Private / Other	(8,607)			(8,607)	0	(8,607)
22 Total	(88,888)	0	0	(88,888)	(11,128)	(85,016)

Section B - By Directorate		Full Year Effect of Actions		Subtotal	Net Year Effect of Undigested Demand (€m)	IMTP Underlying Position of
		Underlying Position of	Recurring Savings (€m)			
	€'000	€'000	Recurring Allocations (Income) (€m)	€'000	€'000	€'000
1 Primary Care	(1,165)			(1,165)	0	(1,165)
2 Mental Health	1,810			1,810	(80)	1,610
3 Community Health Care	(1,264)			(1,264)	0	(1,264)
4 Commissioned Services	(11,817)			(11,817)	1,000	(10,817)
5 Uncontracted Care	(11,869)			(11,869)	7,058	(4,811)
6 Uncontracted Care	(46,000)			(46,000)	(7,021)	(53,021)
7 Children & Young People	(5,365)			(5,365)	(40)	(5,365)
8 Community Services	77			77	0	77
9 Specialist Services	(8,187)			(8,187)	(10,512)	(18,699)
10 Executive & Corporate Areas	(3,176)			(3,176)	(211)	(3,387)
11 Support Services (inc. Estates & Facilities)	(1,223)			(1,223)	(232)	(1,455)
12 Total	(88,888)	0	0	(88,888)	(11,128)	(85,016)

Table A2 - Overview Of Key Risks & Opportunities		FORECAST YEAR END	
		£'000	Likelihood
Opportunities to achieve IMTP/AOP (positive values)			
1	Rad Pipeline schemes (inc AG & IG)		
2	Potential Cost Reduction		
3	Total Opportunities to achieve IMTP/AOP	0	
Risks (negative values)			
4	Under Delivery of Amber Schemes included in Outturn via Tracker		
5	Continuing Healthcare		
6	Prescribing		
7	Pharmacy Contract		
8	WHSCC Performance		
9	Other Contract Performance		
10	GMS Ring Fenced Allocation Underspend Potential Claw back		
11	Dental Ring Fenced Allocation Underspend Potential Claw back		
12	COVID-19 Transitional Funding in excess of Month 8 forecast	(256)	Low
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25	Total Risks	(256)	
Further Opportunities (positive values)			
27	Targeted work programmes		
28			
29			
30			
31			
32			
33	Total Further Opportunities	0	
34	Current Reported Forecast Outturn	(99,000)	
35	IMTP / AOP Outturn Scenario	(99,000)	
36	Worst Case Outturn Scenario	(99,256)	
37	Best Case Outturn Scenario	(99,000)	
38			

Table B - Monthly Positions

[illegible]

Table B2 - Pay Expenditure Analysis

A - Pay Expenditure		1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position
		Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar		
REF	TYPE	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
1	Administrative, Clinical & Board Members	6,415	6,432	6,444	6,384	6,454	6,448	6,679	5,930	7,072	7,127	7,042	7,048	87,784	81,874
2	Medical & Dental	9,385	9,369	9,367	9,364	10,017	11,427	10,668	8,699	12,018	10,418	10,524	10,486	100,824	121,824
3	Nursing & Midwifery Registered	13,881	13,881	14,135	14,134	13,807	17,261	14,725	12,172	14,883	13,321	15,427	16,614	144,185	178,376
4	Prof Scientific & Technical	1,306	1,375	1,339	1,310	1,383	1,750	1,267	1,081	1,430	1,467	1,465	1,646	13,688	16,949
5	Additional Clinical Services	6,123	6,025	6,068	6,133	6,022	6,374	6,301	5,022	6,650	5,345	6,458	6,432	52,386	73,246
6	Allied Health Professionals	3,043	3,041	3,124	3,051	3,034	3,734	3,337	2,889	3,226	3,220	3,188	3,188	31,697	38,073
7	Healthcare Scientists	879	863	867	862	868	1,100	868	688	1,000	865	1,001	1,001	10,016	12,818
8	Estates & Ancillary	2,509	2,432	2,359	2,475	2,308	3,215	2,518	1,804	2,382	2,375	2,351	2,047	24,116	26,365
9	Students	3	3	3	3	2	6	0	0	0	0	0	0	17	17
10	TOTAL PAY EXPENDITURE	43,822	43,223	43,884	43,997	43,813	50,391	46,723	39,166	48,377	47,262	47,814	48,012	450,315	551,158
Analysis of Pay Expenditure															
11	LARS Provided Services - Pay	42,671	42,155	42,637	42,981	42,430	53,901	48,945	37,592	46,347	45,838	46,339	46,434	440,866	533,739
12	Other Services (incl. Primary Care) - Pay	952	1,068	1,037	1,146	1,375	1,490	1,378	1,678	2,879	1,443	1,675	1,578	16,345	17,483
13	Total - Pay	43,623	43,223	43,684	43,997	43,814	50,391	46,723	39,166	48,226	47,281	47,914	48,012	456,511	551,231
B - Agency / Locum (premium) Expenditure															
- Analysed by Type of Staff															
REF	TYPE	1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position
		Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000
1	Administrative, Clinical & Board Members	27	28	30	9	5	5	121	250	8	17	5	5	84	84
2	Medical & Dental	400	646	627	459	463	511	529	630	463	465	528	516	5,116	5,146
3	Nursing & Midwifery Registered	1,871	2,109	2,258	2,284	2,123	2,632	2,510	2,614	2,339	2,696	2,628	2,777	23,887	28,320
4	Prof Scientific & Technical	2	2	2	2	2	2	2	2	2	2	2	2	2	2
5	Additional Clinical Services	2	2	1	18	11	17	17	21	21	22	28	38	83	109
6	Allied Health Professionals	125	131	110	47	106	113	174	130	146	137	128	128	1,279	1,555
7	Healthcare Scientists	48	35	55	55	76	45	46	58	31	34	23	23	472	618
8	Estates & Ancillary	16	6	21	16	8	8	7	8	11	10	10	97	97	117
9	Students	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	TOTAL AGENCY/LOCUM (PREMIUM) EXPENDITURE	2,372	2,863	2,989	2,792	2,812	3,406	3,238	3,691	3,848	3,665	3,336	3,497	31,127	37,665
11	Agency/Locum (premium) % of pay	5.4%	6.6%	6.8%	6.2%	6.2%	6.8%	6.9%	9.2%	9.2%	7.8%	7.0%	7.2%	6.9%	6.8%
C - Agency / Locum (premium) Expenditure															
- Analysed by Reason for Using Agency/Locum (premium)															
REF	REASON	1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position
		Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000
1	Vacancy	1,858	2,307	2,338	2,409	2,415	3,158	2,850	3,194	2,680	3,103	2,921	3,084	28,981	33,346
2	Maternity/Paternity/Adoption Leave	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3	Special Leave (Paid) - inc. compassionate leave, interview	2	3	3	3	3	3	4	3	4	3	4	3	31	37
4	Special Leave (Unpaid)	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5	Study Leave/Examinations	0	0	0	0	0	0	0	0	0	0	0	0	0	0
6	Additional Activity (Other Pressures/Site Pressures)	180	238	239	262	268	288	284	284	284	284	284	284	2,499	3,037
7	Annual Leave	0	0	0	0	0	0	0	0	0	0	0	0	10	21
8	Sickness	86	72	72	75	75	86	87	86	83	86	81	85	816	1,044
9	Respite/Cover Duties	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	Jury Service	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11	WOL	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	Exclusion (Suspension)	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13	COVID-19	256	327	342	33	86	40	77	40	40	40	40	39	1,337	1,465
14	TOTAL AGENCY/LOCUM (PREMIUM) EXPENDITURE	2,372	2,863	2,989	2,792	2,812	3,406	3,238	3,691	3,848	3,665	3,336	3,497	31,127	37,665

A - Additional Expenditure

Table C - Identified Expenditure Savings Schemes (Excludes Income Generation & Accountancy Gains)

		1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Full-year forecast	FTD as %age of FY FTD variance as %age of FTD Budget/Plan	Assessment		Full In-Year forecast		Full-Year Effect of Resource Savings £'000
		Apr £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000				Green £'000	Amber £'000	non recording £'000	recording £'000	
1	Budget/Plan	0	0	0	0	0	0	0	200	0	0	0	0	200	200	200	200	0	200	0	
2	CHC and Funded Nursing Care	0	0	0	0	0	0	0	200	0	0	0	0	200	200	100.00%	200	0	200	0	0
3	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-0.00%	0	0	0	0	0
4	Budget/Plan	100	100	100	100	100	100	100	100	100	100	100	100	1,000	1,200	1,200	1,200	0	1,200	0	
5	Commissioned Services	100	100	100	100	100	100	100	100	100	100	100	100	1,000	1,200	83.33%	1,200	0	1,200	0	0
6	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-0.00%	0	0	0	0	0
7	Budget/Plan	49	48	53	51	49	53	48	51	53	148	148	153	600	900	66.75%	900	0	900	0	0
8	Medicines Management (Primary & Secondary Care)	49	48	53	51	49	53	48	51	53	148	148	153	600	900	66.75%	900	0	900	0	0
9	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-0.00%	0	0	0	0	0
10	Budget/Plan	43	43	50	46	46	50	43	46	49	130	130	131	511	2,409	3,078	3,078	0	3,078	0	884
11	Non Pay	43	43	50	46	46	50	43	46	49	130	130	131	511	2,409	68.78%	3,078	0	2,758	743	0
12	Variance	0	0	0	0	0	246	41	41	41	41	41	41	408	489	15.14%	489	0	0	0	0
13	Budget/Plan	821	879	599	599	528	528	557	557	558	558	557	558	5,941	7,558	7,558	7,558	0	7,558	0	102
14	Pay	821	879	599	599	528	528	557	557	558	558	557	558	5,941	7,558	84.20%	7,558	0	7,005	51	0
15	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-0.00%	0	0	0	0	0
16	Budget/Plan	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17	Primary Care	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
19	Budget/Plan	1,013	889	1,652	1,075	743	748	1,319	1,024	789	1,229	903	1,022	10,440	12,368	12,368	12,368	0	12,368	0	794
20	Total	1,013	889	1,652	1,075	743	748	1,319	1,024	789	1,229	903	1,022	10,440	12,368	84.59%	12,368	0	12,061	955	0
21	Variance	0	0	0	0	0	246	41	41	41	41	41	41	408	489	3.91%	489	0	0	0	0
22	Variance in month	0.00%	0.00%	0.00%	0.00%	0.00%	52.71%	3.12%	4.06%	5.16%	3.31%	4.51%	3.99%								
23	In month achievement against	7.88%	6.70%	12.05%	6.37%	5.78%	7.72%	10.58%	6.13%	6.48%	9.88%	7.34%	6.27%								

Table D - Income/Expenditure Assumptions						
Annual Forecast						
LHB/Trust	Contracted Income £'000	Non Contracted Income £'000	Total Income £'000	Contracted Expenditure £'000	Non Contracted Expenditure £'000	Total Expenditure £'000
1 Swansea Bay University	3,869	529	4,398	37,337	3,399	40,736
2 Aneurin Bevan University	368	427	795	300	16	316
3 Betsi Cadwaladr University	4,991	254	5,245	238	16	254
4 Cardiff & Vale University	345	279	624	6,097	834	6,931
5 Coam Tal Morgannwg University	493	72	565	483	297	780
6 Hywel Dda University			0			0
7 Phylis	7,810	1,047	8,857	198	70	268
8 Public Health Wales	2,738	442	3,180	1,708	563	2,261
9 Valindia		5,136	5,136	15,205	7,431	22,636
10 NHSUW			0			0
11 DHCW	453		453	3,761		3,761
12 Wales Ambulance Services		87	87		2,230	2,230
13 WHHS	1,735		1,735	87,838	(1,690)	86,148
14 EASC			0	31,661	66	31,727
15 HEDW		8,773	8,773		3	3
16 NHS Wales Executive			0			0
17	Total	22,960	18,056	40,894	13,225	198,119

Table E - Resource Limits		STATUS OF ISSUED RESOURCE LIMIT ITEMS				Total Revenue Resource Limit £'000	Recurring (R) or Non Recurring (NR)	Total Revenue Drawing Limit £'000	Total Capital Resource Limit £'000	Total Capital Drawing Limit £'000
1. BASE ALLOCATION		HCHS £'000	Pharmacy £'000	Dental £'000	GMS £'000					
1. LATEST ALLOCATION LETTER/SCHEDULE REF:		85	2	3	8					
2. Total Confirmed Funding		913,264	22,248	20,818	78,787	1,035,097		1,012,382	33,165	33,165
2. ANTICIPATED ALLOCATIONS										
3. DEL Non Cash Depreciation - Baseline Surplus / Shortfall		0				0	NR			
4. DEL Non Cash Depreciation - Strategic		0				0	NR			
5. DEL Non Cash Depreciation - Accelerated		0				0				
6. DEL Non Cash Depreciation - Impairment		0				0				
7. DEL Non Cash Depreciation - IFRS 16 Leases		2,158				2,158	NR			
8. AME Non Cash Depreciation - IFRS 16 Leases (Peppercorn)		8				8	NR			
9. AME Non Cash Depreciation - Donated Assets		709				709	NR			
10. AME Non Cash Depreciation - Impairment		11,616				11,616	NR			
11. AME Non Cash Depreciation - Impairment Reversals		3,409				3,409	NR			
12. Removal of Donated Assets / Government Grant Receipts		(707)				(707)	NR			
13. Total COVID-19 (see below analysis)		3,618	0	0	299	3,917		3,817		
14. Removal of IFRS 16 Leases (Revenue)		(2,091)				(2,091)	NR	(2,091)		
15. Energy (Price Increases)		2,672				2,672	NR	2,672		
16. Employers NI Increases (1.25%)		0				0				
17. Real Living Wage		(945)				(945)				
18. Children & Young Peoples Mental Health & Emotional Wellbeing		200				200	R	200		
19. EASC/MAST Improvements in MH emergency calls		42				42	R	42		
20. WHSSC CAMHS		86				86	R	86		
21. Urgent and Emergency Care		1,477				1,477	R	1,477		
22. Six Goals for Urgent and Emergency Care Programme, Six Goals Improvement Thumwate Tr		160				160	NR	160		
23. Overtime during Annual Leave (MF12 2021/22)		190				190	NR	190		
24. VSHC Aboln Facilitation Redesign regional response		217				217	NR	217		
25. Memory Assessment Services West Wales RPB 2021/22		(196)				(196)	NR	(196)		
26. Bro Myddin and CYP Sanchwari		238				238	NR	238		
27. Working Balance - Revenue						0		14,700		2,146
28. Capital Drawing Limit only						0				8,660
29. Working Balance - Capital						0				
30. Strategic cash						0		62,300		
31. WG Optimality contract for OOH Services					140	140	NR	140		
32						0		0		
33						0		0		
34						0		0		
35										
36										
37										
38										
39										
40										
41										
42										
43										
44										
45										
46										
47										
48										
49										
50										
51										
52										
53										
54										
55										
56 Total Anticipated Funding		22,971	0	0	439	23,410		73,902	0	7,806
3. TOTAL RESOURCES & BUDGET RECONCILIATION										
57 Confirmed Resources Per 1. above		913,264	22,248	20,818	78,787	1,035,097		1,012,382	33,165	33,165
58 Anticipated Resources Per 2. above		22,971	0	0	439	23,410		73,902	0	7,806
59 Total Resources		936,235	22,248	20,818	79,226	1,058,507		1,086,284	33,165	40,971
ANALYSIS OF WG FUNDING FOR COVID-19 INCLUDED ABOVE		Allocated Total £'000	Anticipated HCHS £'000	Anticipated Pharmacy £'000	Anticipated Dental £'000	Anticipated GMS £'000	Total RRL £'000			
60 Testing (inc Community Testing)		929	175				1,108			
61 Tracing		2,494	423				2,917			
62 Mass COVID-19 Vaccination		5,900	982				6,782			
63 PPE		1,832	357				1,889			
64 Extended Flu		943	(209)			299	943			
65 Cleaning Standards		833	448				1,281			
66 Long Covid			359				359			
67 A2 Increased bed capacity specifically related to COVID-19		1,530	468				1,998			
68 A3 Other Capacity & facilities costs		641	222				863			
69 B1 Prescribing changes directly related to COVID symptoms		776	0				776			
70 C1 Increased workforce costs as a direct result of the COVID response and IP&C guidance		1,054	20				1,074			
71 D1 Discharge Support		299	(36)				261			
72 D6 Support for National Programmes through Shared Service							0			
73 D5 Other Services that support the ongoing COVID response		785	306				1,091			
74 E1 Primary Care Contractor (excluding drugs) - Costs as a result of lost GDS income		1,089					1,089			
75										
76										
77										
78										
79										
80										
81										
82										
83										
84										
85										
86										
87										
88										
89										
90 Total Funding		18,505	3,518	0	0	299	22,322			

Table F - Statement of Financial Position For Monthly Period		Opening Balance	Closing Balance	Least Closing Balance
To complete from Month 1		Beginning of	End of	End of
		Apr 22	Jan 23	Mar 23
		£'000	£'000	£'000
Non-Current Assets				
1	Property, plant and equipment	311,562	307,917	343,141
2	Intangible assets	2,784	2,220	2,220
3	Trade and other receivables	168,964	73,696	68,904
4	Other financial assets	0	0	0
5	Non-Current Assets sub-total	483,246	430,636	414,265
Current Assets				
6	Inventory	10,399	10,889	15,399
7	Trade and other receivables	53,283	64,242	53,283
8	Other financial assets	0	0	0
9	Cash and cash equivalents	1,960	2,420	1,960
10	Non-current assets classified as held for sale	0	0	0
11	Current Assets sub-total	65,249	67,551	64,644
12	TOTAL ASSETS	548,495	498,186	478,909
Current Liabilities				
13	Trade and other payables	175,380	144,655	141,111
14	Borrowings (Trust Only)	0	0	0
15	Other financial liabilities	0	0	0
16	Provisions	22,400	29,246	29,246
17	Current Liabilities sub-total	197,780	173,761	170,357
18	NET ASSETS LESS CURRENT LIABILITIES	350,715	324,425	308,552
Non-Current Liabilities				
19	Trade and other payables	0	11,736	11,736
20	Borrowings (Trust Only)	0	0	0
21	Other financial liabilities	0	0	0
22	Provisions	70,059	66,955	66,955
23	Non-Current Liabilities sub-total	70,059	78,693	78,693
24	TOTAL ASSETS EMPLOYED	200,650	245,642	229,899
FINANCED BY:				
Taxpayers' Equity				
25	General Fund	168,450	160,230	176,189
26	Resignation Reserve	32,200	53,710	53,710
27	FSC (Trust only)	0	0	0
28	Retained earnings (Trust Only)	0	0	0
29	Other reserves	0	0	0
30	Total Taxpayers' Equity	200,650	245,642	229,899
EXPLANATION OF ALL PROVISIONS		Opening Balance	Closing Balance	Closing Balance
		Beginning of	End of	End of
		Apr 22	Jan 23	Mar 23
		£'000	£'000	£'000
31	EXPLANATION OF ALL PROVISIONS	83,819	88,836	88,836
32	Credit impairment	939	806	806
33	Redress	4,610	3,888	3,888
34	Personal injury	1,451	1,411	1,411
35	Defence fees	923	923	923
36	2019-20 Scheme Pays - Reimbursement	11	1	1
37	Pensions	706	410	410
38	Other			
39	Total Provisions	92,459	96,200	96,200
ANALYSIS OF WELSH NHS RECEIVABLES (current month)			£'000	
41	Welsh NHS Receivables Aged 0 - 10 weeks		3,639	
42	Welsh NHS Receivables Aged 11 - 16 weeks		225	
43	Welsh NHS Receivables Aged 17 weeks and over		215	
44	ANALYSIS OF TRADE & OTHER PAYABLES (opening, current & closing)	£'000	£'000	£'000
44	Capital	20,504	18,689	12,698
45	Revenue	124,876	137,564	145,151
ANALYSIS OF CASH (opening, current & closing)		£'000	£'000	£'000
46	Capital	490	(3,307)	500
47	Revenue	1,078	2,960	600

Table G - Monthly Cashflow Forecast														
	April £'000	May £'000	June £'000	July £'000	Aug £'000	Sept £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000	Total £'000	
RECEIPTS														
1 WG Revenue Funding - Cash Limit (excluding NCL) - LHB & SHA only	93,127	91,127	91,127	94,127	83,127	105,398	94,187	90,322	94,268	94,668	93,187	71,619	1,086,294	
2 WG Revenue Funding - Non Cash Limited (NCL) - LHB & SHA only	(127)	(127)	(127)	(127)	(127)	(368)	(187)	(522)	(268)	(168)	(187)	(161)	(2,320)	
3 WG Revenue Funding - Other (e.g. invoices)	466	121	0	240	2,756	278	130	130	269	120	600	800	5,565	
4 WG Capital Funding - Cash Limit - LHB & SHA only	14,300	1,300	2,500	2,700	0	3,500	200	1,800	2,035	2,235	6,300	4,000	40,971	
5 Income from other Welsh NHS Organisations	6,226	3,722	6,802	2,705	5,181	4,510	5,458	3,885	8,828	3,106	2,500	10,083	63,086	
6 Short Term Loans - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0	
7 PDC - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0	
8 Interest Receivable - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0	
9 Sale of Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	
10 Other - (Specify in narrative)	3,645	2,063	2,963	1,528	2,356	3,368	2,929	2,950	2,261	2,961	3,879	8,076	38,979	
11 TOTAL RECEIPTS	117,867	98,206	103,285	101,242	93,293	116,656	97,722	96,887	107,833	102,823	106,179	94,117	1,232,480	
PAYMENTS														
12 Primary Care Services - General Medical Services	5,629	5,169	6,513	5,029	4,890	5,434	5,499	6,050	7,841	5,989	5,226	5,182	68,731	
13 Primary Care Services - Pharmacy Services	3,332	0	2,018	1,938	1,826	3,305	0	1,697	3,920	0	1,439	1,400	20,975	
14 Primary Care Services - Prescribed Drugs & Appliances	11,460	0	5,805	6,074	5,785	12,255	0	6,019	12,703	0	7,662	7,665	75,419	
15 Primary Care Services - General Dental Services	1,471	1,410	1,403	1,400	1,594	1,364	1,368	1,382	1,644	1,464	1,450	1,450	17,469	
16 Non Cash Limited Payments	(117)	(221)	(125)	(222)	(244)	(222)	(251)	(250)	(251)	(251)	(251)	(251)	(2,506)	
17 Salaries and Wages	41,285	42,438	41,464	42,053	41,255	45,746	45,079	43,891	43,395	43,362	44,257	44,261	522,047	
18 Non Pay Expenditure	42,221	43,987	44,532	42,687	37,853	41,531	40,490	37,660	34,531	40,458	40,212	30,943	485,693	
19 Short Term Loan Repayment - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0	
20 PDC Repayment - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0	
21 Capital Payment	13,480	1,044	1,118	2,350	584	3,723	1,208	2,388	2,988	2,775	5,275	4,120	41,092	
22 Other Items (Specify in narrative)	2,286	871	76	6	13	73	6	11	72	7	524	600	4,545	
23 TOTAL PAYMENTS	121,048	94,716	102,709	100,636	93,166	113,219	96,476	89,443	107,334	102,783	105,776	95,940	1,233,245	
24 Net cash inflow/outflow	(3,181)	3,490	566	807	107	3,437	(1,754)	(256)	169	140	403	(1,823)		
25 Balance b/f	1,664	(1,816)	1,674	2,230	2,837	2,944	6,381	2,627	2,091	2,280	2,420	2,823	2,853	
26 Balance c/f	(1,516)	1,674	2,230	2,837	2,944	6,381	2,627	2,091	2,280	2,420	2,823	1,000		

Table H - PSPP													
30 DAY COMPLIANCE													
PROMPT PAYMENT OF INVOICE PERFORMANCE	Target %	ACTUAL Q1		ACTUAL Q2		ACTUAL Q3		ACTUAL Q4		YEAR TO DATE		FORECAST YEAR END	
		Actual %	Variance %	Actual %	Variance %	Actual %	Variance %	Actual %	Variance %	Actual %	Variance %	Forecast %	Variance %
1 % of NHS Invoices Paid Within 30 Days - By Value	95.0%	99.9%	4.9%	99.3%	4.3%	99.6%	4.6%	-95.0%	-95.0%	99.6%	4.6%	95.0%	0.0%
2 % of NHS Invoices Paid Within 30 Days - By Number	95.0%	95.7%	0.7%	94.5%	-0.5%	96.4%	1.4%	-95.0%	-95.0%	95.6%	0.6%	95.0%	0.0%
3 % of Non NHS Invoices Paid Within 30 Days - By Value	95.0%	97.9%	2.9%	98.5%	3.5%	97.7%	2.7%	-95.0%	-95.0%	97.9%	2.9%	95.0%	0.0%
4 % of Non NHS Invoices Paid Within 30 Days - By Number	95.0%	96.3%	1.3%	93.6%	-1.4%	93.6%	-1.4%	-95.0%	-95.0%	95.0%	0.0%	95.0%	0.0%
10 DAY COMPLIANCE													
PROMPT PAYMENT OF INVOICE PERFORMANCE		ACTUAL Q1		ACTUAL Q2		ACTUAL Q3		ACTUAL Q4		YEAR TO DATE		FORECAST YEAR END	
		Actual %		Actual %		Actual %		Actual %		Actual %		Actual %	
5 % of NHS Invoices Paid Within 10 Days - By Value		58.1%		51.3%		73.7%				62.9%		75.0%	
6 % of NHS Invoices Paid Within 10 Days - By Number		47.1%		39.4%		38.5%				32.8%		50.0%	
7 % of Non NHS Invoices Paid Within 10 Days - By Value		64.4%		69.1%		78.9%				73.9%		50.0%	
8 % of Non NHS Invoices Paid Within 10 Days - By Number		30.6%		48.4%		50.5%				49.5%		50.0%	

14/20

Table J - In Year Capital Scheme Profiles

Ref:	All Wales Capital Programme: Schemes:	Project Manager	In Year Forecast		Capital Expenditure Monthly Profile												YTD £'000	Total £'000	Risk Level	
			Min. £'000	Max. £'000	April £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000				
1	Gargelli - Fire Enforcement works - Phase 1	RE	5,430	5,430	115	280	294	550	487	343	679	487	490	652	651	522	4,357	5,430	Low	
2	Wylubush - Fire Enforcement works - Phase 1	RE	6,559	6,559	328	451	1	746	847	369	653	754	676	756	500	479	5,530	6,559	Low	
3	Norwales - Phase 8 - main	KJ	957	967	120	94	28	40	(2)	46	63	208	71	40	118	135	714	967	Low	
4	IGS - Multi-site projects	RE	322	322	0	0	0	0	0	0	0	0	0	0	150	172	0	322	Low	
5	PPH Demountables	KJ	1,360	1,360	390	(15)	144	56	36	17	70	(12)	28	69	215	363	782	1,360	Low	
6	Fire Enforcement Works - Wylubush Hospital- Decant Ward Fees	RE	188	188	3	65	2	48	(27)	32	32	(29)	2	8	51	0	137	188	Low	
7	Wylubush - Fire Enforcement works less - Phase 2	RE	881	881	0	6	3	3	123	189	123	74	162	149	39	10	832	881	Low	
8	National Programme - Decontamination	RE	654	654	0	0	43	(10)	(27)	14	10	73	16	105	150	272	232	654	Low	
9	National Programme - Fire	RE	126	126	5	3	(8)	33	1	75	0	0	0	0	17	199	126	Low		
10	National Programme - Mental Health	LC	150	150	0	0	0	48	(5)	(4)	0	(13)	(25)	0	119	20	11	150	Low	
11	National Programme - Imaging	GR	136	136	16	24	7	62	8	2	(29)	0	0	0	0	66	70	136	Low	
12	National Programme - Imaging - CT Scanner PPH	GR	1,217	1,217	0	2	0	0	30	268	501	189	(3)	4	0	219	998	1,217	Low	
13	National Programme - Imaging - CT Scanner B&H	GR	872	842	0	4	1	1	81	(10)	47	16	176	303	300	94	648	842	Medium	
14	National Programme - Imaging - DR Rooms	GR	1,887	1,887	0	1	30	33	35	102	231	316	307	78	388	347	1,132	1,887	Low	
15	National Programme - Imaging - Fluoroscopy Rooms	GR	1,569	1,569	0	0	0	0	31	23	1	5	78	66	662	704	283	1,669	Low	
16	Cross Halls Primary Care scheme	RD	365	365	0	14	30	6	6	8	5	5	5	5	140	142	83	365	Low	
17	EDV funding 2102	GR	0	0	0	0	0	0	401	(451)	0	0	0	0	0	0	0	0	Low	
18	Business Continuity Programme - Fees	RE	150	150	0	0	0	0	0	0	26	34	41	(3)	28	26	86	150	Low	
19	Gargelli - Fire Enforcement works - Phase 1	RE	454	454	0	0	0	0	0	0	6	1	119	166	114	48	282	454	Low	
20	DPF - Digital Medicines Transformation Pre-implementation team	AJ	8	8	0	0	0	0	0	0	0	0	5	0	0	0	8	8	Low	
21	Additional Imaging	GR	216	216	0	0	0	0	0	0	9	0	82	(5)	41	95	35	131	216	Low
22	Emergency Department Waiting Area Improvements	RE	458	458	0	0	0	0	0	0	0	0	0	1	109	348	1	458	Low	
23	Energy Saving Schemes	RE	262	262	0	0	0	0	0	0	0	0	0	0	112	150	0	262	Low	
24	Mammography Equipment, Prince Philip Hospital	GR	747	747	0	0	0	0	0	0	0	7	0	93	647	7	747	Low		
25	Fire Safety Works, Prince Philip Hospital	RE	605	605	0	0	0	0	0	0	0	16	0	150	439	16	605	Low		
26	Decant Ward Wylubush Hospital	RE	1,469	1,469	0	0	0	0	0	0	0	0	0	150	719	0	1,469	Low		
27	Year end funding	Various	682	682	0	0	0	0	0	0	0	2	188	150	342	190	682	Low		
28	Sanctuary Provision CYP	LC	391	391	0	0	0	0	0	0	0	0	0	100	291	0	391	Low		
29	Eye Care Funding	AT	65	65	0	0	0	0	0	0	0	0	0	60	5	0	65	Low		
30																	0	0		
34	Sub Total		28,175	28,248	983	929	878	1,602	1,997	1,072	2,367	2,149	2,171	2,627	5,147	6,620	16,473	28,248		
Discretionary:																				
33	IT	AT	200	200	0	34	16	22	(8)	69	37	5	17	0	0	0	209	200	Low	
36	Equipment	GR	2,461	2,461	0	0	0	0	0	411	43	31	0	217	835	923	783	2,461	Low	
37	Statutory Compliance	RE	448	448	0	2	5	2	15	42	17	43	36	87	176	185	185	448	Low	
38	Estates	RE	1,315	1,315	1	3	7	14	34	73	50	142	135	173	423	209	663	1,315	Low	
39	Other	Various	403	403	2	36	39	15	65	40	28	26	35	88	0	315	403	Low		
40	Sub Total		4,826	4,826	3	75	67	53	165	638	183	221	222	461	1,433	1,308	2,085	4,826		
Other Schemes (including IPRS 16 Leases):																				
41	Converted additions	Various	707	707				100					38	100		469	238	707	Low	
42	Equipment disposals	Various	150	150												150	0	150	Low	
43	IPRS 16 Leases	Various	95	99											95		0	99	Low	
44																	0	0		
45																	0	0		
46																	0	0		
47																	0	0		
48																	0	0		
49																	0	0		
61	Sub Total		956	956	0	0	0	100	0	0	0	0	38	100	99	619	238	956		
62	Total Capital Expenditure		33,992	34,022	986	1,004	642	1,765	2,161	1,708	2,550	2,370	2,431	3,188	6,679	8,647	18,796	34,022		

Table K - Capital Disposals									
A: In Year Disposal of Assets									
	Description	Date of Ministerial Approval to Dispose (Land & Buildings only) MM/YY (text format, e.g. Apr 23)	Date of Ministerial Approval to Retain Proceeds > £0.5m MM/YY (text format, e.g. Apr 23)	Date of Disposal MM/YY (text format, e.g. Feb 23)	NBV £'000	Sales Receipts £'000	Cost of Disposals £'000	Gain/ (Loss) £'000	Comments
1	Equipment disposals	10/3	10/3	Jul 22	150	150	0	0	
2								0	
3								0	
4								0	
5								0	
6								0	
7								0	
8								0	
9								0	
10								0	
11								0	
12								0	
13								0	
14								0	
15								0	
16								0	
17								0	
18								0	
19								0	
	Total for in-year				150	150	0	0	

Table N - General Medical Services
Operating Expenditure - ring fenced GMS budget
Required from Month 6

SUMMARY OF GENERAL MEDICAL SERVICES FINANCIAL POSITION					Year to Date	
	LINE NO.	WG Allocation £000's	Current Plan £000's	Forecast Outturn £000's	Variance £000's	
Global Sum	1					31,507
Revised agreed payment	2					162
Total Global Sum and MPFG	3	47,845	42,305	42,442	178	31,549
GPAT Aspiration Payments	4					(1,430)
GPAT Achievement Payments	5					3,369
GPAT Access Achievement Payments	6					0
Total GPAT	7	1,887	3,307	3,380	(173)	2,939
GPAT Enhanced Services (Ex equal data in Section A (ii) Line 31)	8		2,803	2,423	(380)	1,961
National Enhanced Services (Ex equal data in Section A (ii) Line 41)	9		51	51	0	481
Local Enhanced Services (Ex equal data in Section A (ii) Line 95)	10		2,807	2,481	(326)	1,748
Total Enhanced Services (Ex equal data in Section A Line 95)	11	0,600	8,361	8,485	(1,124)	4,129
GPAT Administered (Ex equal data in Section B Line 100)	12		4,306	10,096	10,790	8,437
GPAT Administered (Ex equal data in Section C Line 100)	13		4,785	4,308	(477)	2,925
GPAT Administered (Ex equal data in Section C Line 100)	14		251	212	(38)	(184)
GPAT Administered (Ex equal data in Section C Line 100)	15		4,836	8,724	8,267	6,025
GPAT Administered (Ex equal data in Section C Line 100)	16		8,658	8,701	8,753	1,882
GPAT Administered (Ex equal data in Section C Line 100)	17	19,548	79,086	77,485	(1,601)	58,095
SUPPLEMENTARY INFORMATION						
Directed Enhanced Services Section A (ii)						
Learning Disabilities	18		42	42	0	391
Childhood Immunisation Scheme	19		481	481	0	0
Minor Injuries	20		0	0	0	0
Influenza & Pneumococcal Immunisation Scheme	21		1,040	540	(500)	515
Services for Vulnerable Patients	22		1	1	0	0
Minor Surgical Fees	23		263	263	0	213
NHS GPAT Administered DES						
GPAT Administered (Ex equal data in Section B Line 100)	24		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	25		682	682	0	201
Care Homes	26		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	27		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	28		44	44	0	31
GPAT Administered (Ex equal data in Section B Line 100)	29		27	27	0	18
GPAT Administered (Ex equal data in Section B Line 100)	30		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	31		351	351	0	201
TOTAL Directed Enhanced Services (must equal line 8)	32		2,923	2,493	(430)	1,961
National Enhanced Services A (ii)						
GPAT Administered	33		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	34		250	250	0	213
GPAT Administered (Ex equal data in Section B Line 100)	35		51	51	0	39
GPAT Administered (Ex equal data in Section B Line 100)	36		250	250	0	174
GPAT Administered (Ex equal data in Section B Line 100)	37		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	38		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	39		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	40		0	0	0	0
TOTAL National Enhanced Services (must equal line 9)	41		871	871	0	481
Local Enhanced Services A (ii)						
GPAT Administered	42		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	43		220	220	0	159
GPAT Administered (Ex equal data in Section B Line 100)	44		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	45		515	515	0	401
GPAT Administered (Ex equal data in Section B Line 100)	46		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	47		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	48		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	49		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	50		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	51		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	52		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	53		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	54		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	55		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	56		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	57		2	2	0	1
GPAT Administered (Ex equal data in Section B Line 100)	58		30	30	0	0
GPAT Administered (Ex equal data in Section B Line 100)	59		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	60		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	61		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	62		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	63		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	64		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	65		31	31	0	21
GPAT Administered (Ex equal data in Section B Line 100)	66		101	101	0	118
GPAT Administered (Ex equal data in Section B Line 100)	67		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	68		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	69		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	70		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	71		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	72		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	73		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	74		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	75		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	76		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	77		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	78		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	79		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	80		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	81		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	82		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	83		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	84		113	113	0	0
GPAT Administered (Ex equal data in Section B Line 100)	85		873	873	0	621
GPAT Administered (Ex equal data in Section B Line 100)	86		348	348	0	227
GPAT Administered (Ex equal data in Section B Line 100)	87		30	30	0	0
GPAT Administered (Ex equal data in Section B Line 100)	88		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	89		1,072	1,072	0	718
GPAT Administered (Ex equal data in Section B Line 100)	90		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	91		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	92		0	0	0	0
GPAT Administered (Ex equal data in Section B Line 100)	93		3,487	2,481	(1,006)	1,748
TOTAL Local Enhanced Services (must equal line 10)	94		8,361	8,485	(1,124)	4,129

GENERAL MEDICAL SERVICES

Operating Expenditure

Required from Month 6

LHB Administered		WG Allocation	Current Plan	Forecast Outturn	Variance	Year to Date
Section B		£000's	£000's	£000's	£000's	£000's
LHB Administered		LINE NO.				
Doctors Retention Scheme Payments		87				323
Locum Allowances - costs of adoption, paternity & maternity		88				181
Locum Allowances - Cover for Sick Leave		89				0
Locum Allowances - Cover for Suspended Doctors		90				0
Prescribed Band Letters		101				0
Recruitment and Retention (including Golden Hello)		102				0
Appraisal - Appraisal Costs		103				0
Primary Care Development Scheme		104				0
Partnership Payments - GP partners		105				430
Partnership Payments - Non GP Partners		106				0
Supply of syringes & needles		107				7,432
Other (please provide detail below, this should reconcile to line 128)		108				0
TOTAL LHB Administered (must equal line 12)		109	4,304	10,271	10,779	8,641
Analysis of Other Payments (line 108)		LINE NO.	£000's	£000's	£000's	£000's
Additional Managed Practice costs (costs in excess of Global SumMPD)		110				251
CBE checks		111				0
CBE costs payments		112				0
LHB Locally group costs		113				4,841
Managing Practice costs (LHB employed staff working in GP practices to improve GP services)		114				0
Primary Care Initiatives		115				0
Salaries GP costs		116				60
Stationery & Distribution		117				0
Training		118				1,742
Registration fees		119				170
GP/Practice related payments to GP practices		120				10
Cooperative fees		121				170
Laboratory fees		122				10
Packaging and transport		123				0
Recruitment		124				60
Prescribing Incentive Scheme		125				0
Other GMS costs		126				0
TOTAL of Other Payments (must equal line 108)		127				7,432
Premises		Section C	LINE NO.	£000's	£000's	£000's
National Beds		128				1,140
Actual Beds Health Centres		129				0
Actual Beds Clinics		130				1,110
Cost Rent		131				142
Clinical Waste Trade Refuse		132				430
Heating, Water, sewerage etc		133				110
Health centre Charges		134				0
Improvement Grants		135				0
All other Premises (please detail below which should reconcile to line 146)		136				0
TOTAL Premises (must equal line 13)		137	4,762	4,301	3,031	868
Analysis of Other Premises (line 137)		LINE NO.	£000's	£000's	£000's	£000's
		138				
		139				
		140				
		141				
		142				
		143				
		144				
		145				
		146				
TOTAL of Other Premises (must equal line 137)		147				0
Water/sewerage rates		148				
Enhanced Services included above but in dispute with LMC (TOTAL)						
Enhanced Services included above but not yet formally agreed LMC						

GENERAL MEDICAL SERVICES

Dispensing

Dispensing Data		WG Allocation	Current Plan	Forecast Outturn	Variance	Year to Date
Section B		£000's	£000's	£000's	£000's	£000's
Cost of Drugs and Appliances, after discounts and plus container allowance (and plus VAT where applicable)		LINE NO.				
Dispensing Section		149				3,951
Prescription Medical Practitioners - Personal Administration		150				0
Dispensing Section Locality Payment		151				0
Professional Fees and on-cost		152				1,504
Dispensing Section		153				0
Prescribing Medical Practitioners - Personal Administration		154	5,650	5,701	6,763	5,548
TOTAL DISPENSING DATA (must equal line 16)		155				

Table O - General Dental Services					
Operating Expenditure from the revenue allocation for the dental contract					
Required from Month 6					
SUMMARY OF DENTAL SERVICES FINANCIAL POSITION					
Expenditure Activities included in a DDS contract and / or FDS agreement	LINE NO	WG Allocation	Current Plan	Forecast Outturn	Variance
		£000's	£000's	£000's	£000's
Gross Contract Value - Personal Dental Services	1		17,833	18,403	570
Gross Contract Value - General Dental Services	2				0
Emergency Dental Services (in Out of hours)	3				0
Additional Access	4		64	109	45
Business Rates	5				0
Domiliary Services	6		40	64	24
Maternity/Childcare etc.	7				0
Sedation services including GA	8				0
Emergency payments	9				0
Employer's Superannuation	10		658	758	100
Other staff	11				0
OTHER					
PLEASE DETAIL	12		3,913	3,779	(134)
BELOW					
TOTAL DENTAL SERVICES EXPENDITURE	13	20,816	22,826	23,184	358
agreement. This includes payments made under other arrangements e.g. GA under an SLA and DDS, plus	LINE NO		£000's	£000's	£000's
Emergency Dental Services (in Out of hours)	14				
Additional Access	15				
Sedation services including GA	16			480	
Continuing professional development	17				
Occupational Health / Infection G	18				
Green Am Byts - Oral Health in care homes	19				
Refund of patient charges	20			2	
Dispute & Sols	21			476	
Other Community Dental Services	22			1,684	
Dental Education Training/Continual Training	23			368	
DBS/CPS checks	24				
Health Board staff costs associated with the delivery / monitoring of the dental contract	25			85	
Oral Surgery	26			551	
Oral Radiology	27				
Special care dentistry e.g. WHC/2016/002	28				
Oral Health Promotion/Education	29				
Insurance expenditure in dental practices	30				
Alford Anywhere	31			527	
Other	32				
Other income	33			(614)	
	34				
	35				
	36				
	37				
	38				
	39				
	40				
	41				
TOTAL OTHER (must equal line 13)	42			3,779	
	43				
TOTAL DENTAL SERVICES INCOME (Enter as a negative value)	44		(2,875)	(3,938)	142
					(1,346)